<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6747533</article-id><article-id pub-id-type="doi">10.3390/ijms20174291</article-id><article-id pub-id-type="publisher-id">ijms-20-04291</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Progress in Research on the Role of Flavonoids in Lung Cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9574-0914</contrib-id><name><surname>Zanoaga</surname><given-names>Oana</given-names></name><xref ref-type="aff" rid="af1-ijms-20-04291">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3055-4747</contrib-id><name><surname>Braicu</surname><given-names>Cornelia</given-names></name><xref ref-type="aff" rid="af1-ijms-20-04291">1</xref><xref rid="c1-ijms-20-04291" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Jurj</surname><given-names>Ancuta</given-names></name><xref ref-type="aff" rid="af1-ijms-20-04291">1</xref></contrib><contrib contrib-type="author"><name><surname>Rusu</surname><given-names>Alexandru</given-names></name><xref ref-type="aff" rid="af2-ijms-20-04291">2</xref><xref ref-type="aff" rid="af3-ijms-20-04291">3</xref></contrib><contrib contrib-type="author"><name><surname>Buiga</surname><given-names>Rares</given-names></name><xref ref-type="aff" rid="af3-ijms-20-04291">3</xref><xref ref-type="aff" rid="af4-ijms-20-04291">4</xref><xref rid="c1-ijms-20-04291" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3856-3784</contrib-id><name><surname>Berindan-Neagoe</surname><given-names>Ioana</given-names></name><xref ref-type="aff" rid="af1-ijms-20-04291">1</xref><xref ref-type="aff" rid="af5-ijms-20-04291">5</xref><xref ref-type="aff" rid="af6-ijms-20-04291">6</xref></contrib></contrib-group><aff id="af1-ijms-20-04291"><label>1</label>Research Center for Functional Genomics and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 23 Marinescu Street, 40015 Cluj-Napoca, Romania</aff><aff id="af2-ijms-20-04291"><label>2</label>Biozoon GmbH, D-27572 Bremerhaven, Germany</aff><aff id="af3-ijms-20-04291"><label>3</label>Department of Pathology, &#x0201c;Prof. Dr. Ion Chiricuta&#x0201d; Oncology Institute, 400015 Cluj-Napoca, Romania</aff><aff id="af4-ijms-20-04291"><label>4</label>Department of Pathology Iuliu Hatieganu, University of Medicine and Pharmacy, 400015 Cluj-Napoca, Romania</aff><aff id="af5-ijms-20-04291"><label>5</label>MEDFUTURE-Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania, 23 Marinescu Street, 40015 Cluj-Napoca, Romania</aff><aff id="af6-ijms-20-04291"><label>6</label>Department of Functional Genomics and Experimental Pathology, The Oncology Institute &#x0201c;Prof. Dr. Ion Chiricuta&#x0201d;, Republicii 34th street, 400015 Cluj-Napoca, Romania</aff><author-notes><corresp id="c1-ijms-20-04291"><label>*</label>Correspondence: <email>cornelia.braicu@umfcluj.ro</email> (C.B.); <email>raresbuiga@yahoo.fr</email> (R.B.)</corresp></author-notes><pub-date pub-type="epub"><day>02</day><month>9</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2019</year></pub-date><volume>20</volume><issue>17</issue><elocation-id>4291</elocation-id><history><date date-type="received"><day>21</day><month>8</month><year>2019</year></date><date date-type="accepted"><day>30</day><month>8</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 by the authors.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Lung cancer is the leading cause of cancer deaths worldwide. Therefore, for the prevention, diagnosis, prognosis and treatment of lung cancer, efficient preventive strategies and new therapeutic strategies are needed to face these challenges. Natural bioactive compounds and particular flavonoids compounds have been proven to have an important role in lung cancer prevention and of particular interest is the dose used for these studies, to underline the molecular effects and mechanisms at a physiological concentration. The purpose of this review was to summarize the current state of knowledge regarding relevant molecular mechanisms involved in the pharmacological effects, with a special focus on the anti-cancer role, by regulating the coding and non-coding genes. Furthermore, this review focused on the most commonly altered and most clinically relevant oncogenes and tumor suppressor genes and microRNAs in lung cancer. Particular attention was given to the biological effect in tandem with conventional therapy, emphasizing the role in the regulation of drug resistance related mechanisms.</p></abstract><kwd-group><kwd>flavonoids</kwd><kwd>lung cancer</kwd><kwd>cellular signaling pathways</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-ijms-20-04291"><title>1. Introduction</title><p>Lung cancer is one of the most dangerous types of cancer for both men and women with an increasing number of deaths each year and a survival rate lower than other types of malignancies, that is, with overall 5-year survival rates of 10&#x02013;20% in most countries [<xref rid="B1-ijms-20-04291" ref-type="bibr">1</xref>,<xref rid="B2-ijms-20-04291" ref-type="bibr">2</xref>]. According to GLOBOCAN 2018, it was estimated that lung cancer is the most commonly diagnosed cancer (11.6% of the total cases) and the leading cause of cancer death (18.4% of the total cancer deaths) accounting for 2.1 million new cases and 1.8 million deaths in 2018 [<xref rid="B3-ijms-20-04291" ref-type="bibr">3</xref>].</p><p>In spite of the progress in treatment options involving surgery, radiation, chemotherapy and specific targeted therapies, the prognosis remains unsatisfactory due to the late diagnosis, being related to the appearance of metastatic disease [<xref rid="B4-ijms-20-04291" ref-type="bibr">4</xref>,<xref rid="B5-ijms-20-04291" ref-type="bibr">5</xref>]. A considerable number of genomic studies associate lung cancer with <italic>TP53</italic> (tumor protein 53), <italic>PTEN</italic> (phosphatase and tensin homolog deleted on chromosome 10) and <italic>PI3K/Akt</italic> (phosphatidylinositol-3-kinase) mutations [<xref rid="B6-ijms-20-04291" ref-type="bibr">6</xref>], RTK alteration (receptor of tyrosine kinase like <italic>EGFR</italic> (epidermal growth factor receptor), <italic>MET</italic>, <italic>ROS1</italic> (reactive oxygen species), <italic>ALK</italic> (anaplastic lymphoma kinase) and <italic>RET</italic> (proto-oncogene tyrosine-protein kinase receptor) [<xref rid="B7-ijms-20-04291" ref-type="bibr">7</xref>]. These genomic alterations affect multiple cellular functions, including the cell growth, differentiation, proliferation, survival, motility, invasion and intracellular trafficking. The association of activating <italic>RTK</italic> mutations, giving enlarged sensitivity and disease response to RTK inhibitors, permitted the development of new approaches for the personalized treatment of lung cancer. The comprehensive epigenetic, genomic and molecular characterization of lung cancer has guided the identification of novel targeted therapies based on natural or synthetic small molecules [<xref rid="B5-ijms-20-04291" ref-type="bibr">5</xref>,<xref rid="B8-ijms-20-04291" ref-type="bibr">8</xref>]. The major risk factors for lung cancer, like smoking tobacco and exposure to chemical carcinogens, are sustained by an unhealthy inflammatory diet (low consumption of fruits and vegetables and high salt consumption [<xref rid="B9-ijms-20-04291" ref-type="bibr">9</xref>]). It is known that the Mediterranean diet rich in natural phytochemicals are related to a reduced risk of lung cancer [<xref rid="B10-ijms-20-04291" ref-type="bibr">10</xref>].</p><p>Phytochemicals are natural, plant-derived compounds that have been used for the treatment of various diseases, including cancer. In vitro and in vivo studies have demonstrated their influence on tumor proliferation, growth, and metastasis [<xref rid="B11-ijms-20-04291" ref-type="bibr">11</xref>,<xref rid="B12-ijms-20-04291" ref-type="bibr">12</xref>]. Furthermore, the uses of natural compounds are sustained by their wide availability, high tolerance, and cost-effectiveness when compared to synthetic molecules [<xref rid="B13-ijms-20-04291" ref-type="bibr">13</xref>,<xref rid="B14-ijms-20-04291" ref-type="bibr">14</xref>]. More than 8000 different compounds of polyphenols (phenolic acids, flavonoids, stilbenes, and lignans) are retrieved from natural sources (fruits, vegetables, and seeds) [<xref rid="B15-ijms-20-04291" ref-type="bibr">15</xref>]. Flavonoids belong to the polyphenol class of phytochemicals that include over 4000 members. They have been classified according to their molecular structure that consist of two benzene rings joined by a linear three-carbon chain and form an oxygenated heterocycle (C6-C3-C6) and their large number of functional groups (hydroxyl, methoxyl, and O-glycoside) on the basic benzo-pyrone (C6-C3-C6) structure [<xref rid="B16-ijms-20-04291" ref-type="bibr">16</xref>]. Recent attention has focused on the beneficial actions of natural flavonoids (subdivided as flavones, flavonols, flavanones, flavanols, anthocyanins and isoflavones) [<xref rid="B17-ijms-20-04291" ref-type="bibr">17</xref>,<xref rid="B18-ijms-20-04291" ref-type="bibr">18</xref>]. Since flavonoids incorporate a similar functional structure, the functional diversity is generally attributed to the substituent groups [<xref rid="B19-ijms-20-04291" ref-type="bibr">19</xref>], the chemical structure being presented in <xref ref-type="fig" rid="ijms-20-04291-f001">Figure 1</xref>. Flavonoids exert innumerable beneficial effects on human health and are considered to be a molecular template for the design of novel therapeutic agents for various diseases, including lung cancer. Flavonoids&#x02019; biological effect initially was mainly attributed to their capacity to inhibit reactive oxygen species (ROS) production, a fact that involved a wide range of key cellular processes, affecting several molecular mechanisms altered in tumor cells [<xref rid="B12-ijms-20-04291" ref-type="bibr">12</xref>,<xref rid="B18-ijms-20-04291" ref-type="bibr">18</xref>]. Regarding the association between flavonoids and lung cancer risk, small beneficial effects were observed, especially among never-smokers patients [<xref rid="B17-ijms-20-04291" ref-type="bibr">17</xref>].</p><p>Presently, a single clinical trial on 37 patients with stage III lung cancer was undertaken. In this study, epigallocatechin gallate (EGCG) was given in the concentration of 440 &#x003bc;mol/L during radiotherapy and two weeks after radiotherapy. After the treatment, it was observed that the radiation therapy oncology group (RTOG) score decreased significantly and the pain score of each week was significantly lower than the baseline (<uri>ClinicalTrials.gov</uri> Identifier: NCT02577393). The same results were observed on patients who received oral Polyphenon E twice daily for 3 months in the absence of disease progression or unacceptable toxicity (<uri>ClinicalTrials.gov</uri> Identifier: NCT00611650).</p><p>The purpose of this review is to cluster all the latest investigation presented in the literature concerning the biological effects of natural flavonoids on lung cancer prevention, molecular signaling and therapeutic perspectives, considering the reduced clinical trials for lung cancer.</p></sec><sec id="sec2-ijms-20-04291"><title>2. Anticancer Effects of Flavonoids in Lung Cancer</title><p>Dietary flavonoids are natural compounds being used for many years as nutraceuticals due to their numerous favorable properties on human health. This class of compounds is highly prevalent in fruits, vegetables, whole grains, and plant extracts. Flavonoids are the greatest class of polyphenols responsible for the plant pigmentation. Apart from the color, flavonoids have been proved to be responsible for a wide range biochemical functions in seed maturation, protection from different biotic/abiotic stresses, and heat acclimation and freezing tolerance. Flavonoids were developed as a detoxifying and defensive system in plants [<xref rid="B20-ijms-20-04291" ref-type="bibr">20</xref>], and in mammalians cells, they have a wide range of biological effects presented in <xref ref-type="fig" rid="ijms-20-04291-f002">Figure 2</xref> and <xref rid="ijms-20-04291-t001" ref-type="table">Table 1</xref>.</p><p>Flavones are commonly found in many fruits and plant foods [<xref rid="B21-ijms-20-04291" ref-type="bibr">21</xref>]. The main flavones are apigenin, luteolin and diosmetin which showed potent inhibitory effects on the proliferation, activation of apoptosis and cell cycle regulation, but also invasion and metastasis [<xref rid="B21-ijms-20-04291" ref-type="bibr">21</xref>]. Dietary flavones may serve as preventive/therapeutic agents against different human cancers due to their interfering capacity with epigenetic pathways [<xref rid="B22-ijms-20-04291" ref-type="bibr">22</xref>].</p><p>Flavonols were proved to have important antiproliferative effects [<xref rid="B23-ijms-20-04291" ref-type="bibr">23</xref>], apoptosis also affecting tight junction protein key elements of carcinogenesis [<xref rid="B24-ijms-20-04291" ref-type="bibr">24</xref>], invasion and metastatic processes [<xref rid="B25-ijms-20-04291" ref-type="bibr">25</xref>].</p><p>Flavanones, including hesperidin and naringin, are retrieved in high concentration in citrus, the main biological effects being related to the anti-inflammatory effects [<xref rid="B26-ijms-20-04291" ref-type="bibr">26</xref>]. Furthermore, flavanone derivatives have been shown to play a critical role in the cell cycle regulatory proteins expression control [<xref rid="B27-ijms-20-04291" ref-type="bibr">27</xref>].</p><p>Flavan-3-ols, also found in the literature as catechins, are found in green tea, apples, cocoa, red wine, grapes, and other fruits [<xref rid="B16-ijms-20-04291" ref-type="bibr">16</xref>]. Flavan-3-ols have a wide range of antitumoral effects, due to their capacity to regulate NF&#x003ba;B (nuclear factor-&#x003ba;B), MAPK (mitogen activated protein kinases) or PI3K/Akt signaling, target RTK receptors or pro-angiogenic effectors [<xref rid="B28-ijms-20-04291" ref-type="bibr">28</xref>]. In vitro and in vivo studies demonstrated that quercetin target aurora B kinase directly affected lung cancer cells by the inhibition of proliferation [<xref rid="B23-ijms-20-04291" ref-type="bibr">23</xref>].</p><p>Isoflavones (genistein and daidzein) are abundant in soybeans derivative products and are known as RTK inhibitors, targeting the epidermal growth factor (EGF) and interfering with the cell proliferation, migration, and invasion mechanism [<xref rid="B29-ijms-20-04291" ref-type="bibr">29</xref>]. Most of the studies on isoflavones are related to the antitumoral effects in hormonal dependent-cancer [<xref rid="B19-ijms-20-04291" ref-type="bibr">19</xref>].</p><p>Anthocyanidins are common plant pigments responsible for the blue, purple and red colors and have been associated with many biological activities. Anthocyanidins received attention due to their anti-inflammatory, antioxidant, and cancer-inhibitory properties [<xref rid="B30-ijms-20-04291" ref-type="bibr">30</xref>]. Anthocyanidins reduce the inflammation by the inhibition of NF&#x003ba;B and Wnt signaling, activate mitochondrial apoptosis. Further, they have been proved to be important regulators of the inhibit Akt/mTOR pathway [<xref rid="B30-ijms-20-04291" ref-type="bibr">30</xref>].</p></sec><sec id="sec3-ijms-20-04291"><title>3. Flavonoids as Key Gene Expression Regulators in Lung Cancer</title><p>A number of research studies involving flavonoids provided their role in the prevention and treatment of lung cancer, and have highlighted some of their complex molecular mechanisms of action and potential targets. A couple of important mechanisms comprise of the modulation of carcinogen-metabolizing enzymes, specific cell-cycle arrest and the activation of apoptosis, by the modulation of cell-signaling pathways and the inhibition of the activation of key transcription factors, summarized in <xref rid="ijms-20-04291-t002" ref-type="table">Table 2</xref>. These mechanisms provide a direct consequence for the inhibition of lung cancer development or progression [<xref rid="B38-ijms-20-04291" ref-type="bibr">38</xref>,<xref rid="B39-ijms-20-04291" ref-type="bibr">39</xref>]. All these facts suggest the important preventive/therapeutic actions of flavonoids in lung cancer [<xref rid="B40-ijms-20-04291" ref-type="bibr">40</xref>].</p><sec id="sec3dot1-ijms-20-04291"><title>3.1. Flavonoids Interfere with Receptor Tyrosine Kinases Cascade in Lung Cancer</title><p>RTKs are a family of cell-surface receptors, highly activated in tumoral pathology. The mutations that affect RTK signaling or downstream effectors conduct the cell transformation, which are frequently retrieved in solid tumors [<xref rid="B41-ijms-20-04291" ref-type="bibr">41</xref>]. This makes them important therapeutic targets, including lung cancer. RTK act as receptors for growth factors, hormones, cytokines/chemokine and other extracellular signaling molecules [<xref rid="B41-ijms-20-04291" ref-type="bibr">41</xref>]. RTKs activate signal transduction cascade, being able to mediate key signaling pathways, contribute the regulation of cell proliferation, differentiation, survival and cell migration. Flavonoids have been proved to have the capacity to interfere in this signal transduction cascade (<xref ref-type="fig" rid="ijms-20-04291-f003">Figure 3</xref>).</p><p>Tumor growth can originate from a high rate of cell division and/or a reduction in the rate of cell death. Flavonoids can affect both of these processes, interfering with key regulatory effectors. Flavonoids are presented in the literature as protein kinase inhibitors for cancer. This was demonstrated by studies proving the direct binding or by molecular modeling [<xref rid="B40-ijms-20-04291" ref-type="bibr">40</xref>]. The effect on this kinase function might be independent to the classical antioxidant effect observed [<xref rid="B40-ijms-20-04291" ref-type="bibr">40</xref>], but at the same time the reactive oxygen species (ROS) activated MAPK (mitogen-activated protein kinase) cascade, Janus kinase/signal transducers and the activators of transcription (JAK/STAT) pathways or PI3K (phosphatidylinositol 3-kinase)/Akt (serine/threonine kinase 1) [<xref rid="B42-ijms-20-04291" ref-type="bibr">42</xref>,<xref rid="B43-ijms-20-04291" ref-type="bibr">43</xref>,<xref rid="B44-ijms-20-04291" ref-type="bibr">44</xref>].</p><p>It is well known that the main barrier in cancer treatment is related to the activation of MAPK in a direct relationship with the persistent activation of transcription factors like NF&#x003ba;B (nuclear factor-&#x003ba;B) or AP1 (activator protein 1) [<xref rid="B43-ijms-20-04291" ref-type="bibr">43</xref>]. The activation of NF&#x003ba;B often occurs in lung cancer and contributes to aggressive tumor growth and resistance to chemotherapy and radiotherapy. This factor has proven to be specifically inhibited by dietary flavonoids. After short-term EGCG, the exposure of lung cancer cells was observed in that EGF-induced EGFR, Akt and ERK1/2 activation was substantially decreased [<xref rid="B45-ijms-20-04291" ref-type="bibr">45</xref>]. In vitro studies demonstrated that fisetin inhibited the growth and migration of non-small cell lung cancer by inhibiting the activation of the ERK signaling pathway via MEK1/2 [<xref rid="B46-ijms-20-04291" ref-type="bibr">46</xref>].</p><p>An important molecular target regulated by dietary flavonoids is represented by the PI3K pathway. This signal transduction pathway actively participates in the regulation of cell proliferation and survival, differentiation regulation, cellular adhesion, cell motility, and invasion [<xref rid="B31-ijms-20-04291" ref-type="bibr">31</xref>]. The targeting of the PI3K/Akt pathway might be an attractive therapeutic strategy to overcome the struggle of the clinical challenges of lung cancer tumor heterogeneity and acquired resistance, being important members of the flavonoids that are represented by apigenin and lutein [<xref rid="B31-ijms-20-04291" ref-type="bibr">31</xref>]. Lutein inhibits the PI3K/Akt signaling pathway, leading to a reduced cell proliferation and activation of apoptosis in lung cancer cells [<xref rid="B42-ijms-20-04291" ref-type="bibr">42</xref>].</p><p>The Akt proteins are serine/threonine kinases that function as leading regulators of cellular proliferation and apoptosis. The important role of AKT was demonstrated by multiple studies that discussed their development in lung cancer [<xref rid="B42-ijms-20-04291" ref-type="bibr">42</xref>,<xref rid="B47-ijms-20-04291" ref-type="bibr">47</xref>]. Apigenin was demonstrated to be a new inhibitor of AKT in lung cancer suppressing phosphorylation of Akt and inhibited the gene expression of MMP-9 (matrix metalloproteinases-9), GSK-3 (glycogen synthase kinase-3&#x003b2;), and HEF1 (human enhancer of filamentation 1) [<xref rid="B31-ijms-20-04291" ref-type="bibr">31</xref>]. Naringenin treatment showed significant alteration in lung cancer cell proliferation by the inhibition of AKT and MMP2/9 activities in a dose-dependent manner [<xref rid="B48-ijms-20-04291" ref-type="bibr">48</xref>].</p><p>JAK-STAT3 signaling is activated by the effect of targeting the downstream cytokine receptors, with an impact on a wide range of cellular functions being interrelated with MAPK effectors, Akt or the proteins regulated by cell death machinery (proapototic protein BAD or caspases) which promotes cell survival [<xref rid="B40-ijms-20-04291" ref-type="bibr">40</xref>]. Kaempferol and luteinol decrease claudin-2 expression in A549 cells by the inhibition of the interaction between STAT3 and the promoter region of claudin-2, indicating that kaempferol may directly block the interaction of STAT3 on DNA [<xref rid="B24-ijms-20-04291" ref-type="bibr">24</xref>]. Daidzein action was mediated by restoring the STK4-induced YAP1 phosphorylation, and the components of Hippo pathway STK4 with significant inhibition of lung cancer cells [<xref rid="B49-ijms-20-04291" ref-type="bibr">49</xref>]. A549 and NCI-H358 NSCLC cells after treatment with quercetin have resulted in significant increases of the apoptotic cell population and caspase-3 activity and the loss of MMP in a time- and dose-dependent manner [<xref rid="B50-ijms-20-04291" ref-type="bibr">50</xref>].</p></sec><sec id="sec3dot2-ijms-20-04291"><title>3.2. Flavomoids Affects Cell Proliferation, Apoptosis and Autophagy </title><p>In addition to the repressive effect on cellular proliferation, flavonoids also enhance the rate of cancer cell death [<xref rid="B51-ijms-20-04291" ref-type="bibr">51</xref>] by activating apoptosis and autophagy related mechanisms [<xref rid="B52-ijms-20-04291" ref-type="bibr">52</xref>]. An important effector is represented by TP53. At the same time, TP53 is one of the most frequently mutated genes in lung cancer [<xref rid="B6-ijms-20-04291" ref-type="bibr">6</xref>], being the most extensively studied and related to the inhibition of cell growth and the induction of apoptosis [<xref rid="B6-ijms-20-04291" ref-type="bibr">6</xref>,<xref rid="B53-ijms-20-04291" ref-type="bibr">53</xref>]. Posttranslational modification has a crucial role in the p53 function [<xref rid="B54-ijms-20-04291" ref-type="bibr">54</xref>]. By studying the cisplatin cytotoxic effect on lung cancer cells, researchers have demonstrated that dietary flavonoids, like apigenin, significantly enhanced p53 phosphorylation [<xref rid="B55-ijms-20-04291" ref-type="bibr">55</xref>]. Since apigenin treatment promoted MAPK activation, the increased p53 phosphorylation was revealed to be modulated by MAPK, with the essential role in p53 accumulation and the proapoptotic effect. Furthermore, apigenin was observed to amplify the inhibitory effect on cisplatin proliferation in A549 wild-type p53 cells. This effect was not found in the H1299 p53-null cells. Apoptosis was induced by flavonoids in mice lung tissues injected with A549 cells through the caspase-3 and TP53 pathway, p-TP53 and BAX expression which increased due to flavonoid treatment [<xref rid="B56-ijms-20-04291" ref-type="bibr">56</xref>]. Additionally, apigenin significantly increased the expression of p53 by suppressing the phosphorylation of I&#x003ba;B&#x003b1; and p65 nuclear translocation [<xref rid="B57-ijms-20-04291" ref-type="bibr">57</xref>]. Studies on the effect of quercetin in A549 cells and H1299 cells observed induced-treatment apoptosis in a dose-dependent manner. The cytotoxicity increased after treatment with a specific p53 inhibitor and transfection of a p53 antisense oligodeoxynucleotide [<xref rid="B58-ijms-20-04291" ref-type="bibr">58</xref>]. Flavonoids from <italic>G. pentaphyllum</italic> modulated the expression of A, cyclin B and p53 in A549 cells, but not in H460 cells. The difference between p53 expression in the studied cell lines can be explained by the lack of cell cycle arrest in H460 cells [<xref rid="B59-ijms-20-04291" ref-type="bibr">59</xref>]. In H522 lung cancer cells, hesperetin increased apoptosis which was correlated with the downregulation of p53 levels [<xref rid="B60-ijms-20-04291" ref-type="bibr">60</xref>]. In NSLC A549, luteolin treatment increased the expression of p53 [<xref rid="B61-ijms-20-04291" ref-type="bibr">61</xref>,<xref rid="B62-ijms-20-04291" ref-type="bibr">62</xref>].</p><p>Luteolin inhibited NCI-H460 cell migration in a dose-dependent manner. The anticancer effect of luteolin was induced by Sirt1-mediated activation of the caspase-3 pathway and by the inhibition of the protein expression level of Bad and the Bcl-2/Bax ratio [<xref rid="B63-ijms-20-04291" ref-type="bibr">63</xref>]. In lung cancer cells, luteolin acts as a radiosensitizer by increasing apoptotic cell death through the activation of a p38/ROS/caspase cascade [<xref rid="B33-ijms-20-04291" ref-type="bibr">33</xref>]. In vitro studies on the effect of naringenin in A549 cells demonstrated significant enhancement of TRAIL-induced apoptosis through the induction of DR5 expression [<xref rid="B64-ijms-20-04291" ref-type="bibr">64</xref>]. On H1299 and A549 lung cancer cells, EGCG inhibited the expression of Caspase-3, Bax, and Bcl-2 protein by inhibiting the activation of the PI3K/Akt signaling pathway in a dose-dependent manner [<xref rid="B65-ijms-20-04291" ref-type="bibr">65</xref>]. The antiproliferation and pro-apoptotic effects of genistein on A549 lung adenocarcinoma cells is due to the downregulation of Bcl-2 and upregulation of Bax [<xref rid="B66-ijms-20-04291" ref-type="bibr">66</xref>].</p></sec><sec id="sec3dot3-ijms-20-04291"><title>3.3. Flavonoids as Cell Cycle Modulators</title><p>The cell cycle is a highly regulated process to ensure proper division of the cell, being supervised by a precise set of proteins that act as checkpoints for correct cell division. The balance between these essential proteins is vital. Flavonoids have been demonstrated to interfere in the regulation of the three main checkpoints (G1, G2 and M). Most literature data reveal that flavonoids target proteins that are implicated in the regulation of the G2/M checkpoint. For example, cyclin-dependent kinases (CDKs) are a group of serine/threonine kinases involved in cancer pathology with essential roles in the apoptosis, differentiation and cell division cycle [<xref rid="B67-ijms-20-04291" ref-type="bibr">67</xref>,<xref rid="B68-ijms-20-04291" ref-type="bibr">68</xref>]. Genistein significantly inhibited the proliferation and migration of H446 cells inducing apoptosis and G2/M phase cell cycle arrest. Furthermore, genistein treatment demonstrated that FoxM1 may be a novel therapeutic agent down-regulating a series of FoxM1 target genes involved in the cell cycle and apoptosis, including Cdc25B, cyclin B1, and survivin [<xref rid="B37-ijms-20-04291" ref-type="bibr">37</xref>]. The flavanones. like hesperetin, have anti-inflammatory and anticancer effects in the A549 cells and inhibit IL-1&#x003b2;-stimulated cell proliferation, COX-2 expression and PGE2 synthesis [<xref rid="B69-ijms-20-04291" ref-type="bibr">69</xref>]. Another study on A549 cells reveal that hesperidin have the capacity to induce apoptosis and G0/G1 cell cycle arrest [<xref rid="B35-ijms-20-04291" ref-type="bibr">35</xref>].</p></sec><sec id="sec3dot4-ijms-20-04291"><title>3.4. Flavonoids Regulate Invasion and Metastasis</title><p>Flavonoids have proved to be key regulators of epithelial to mesenchymal transition (EMT) and cell migration and invasion. Liu et al. highlighted the modulation of EMT related effectors, as in lung cancer cells, by the EGCG, having the capacity to inhibit the transforming growth factor &#x003b2; (TGF&#x003b2;) being induced by the EMT mechanism and the inhibition of the phosphorylated form of Smad2 and ERK1/2 [<xref rid="B36-ijms-20-04291" ref-type="bibr">36</xref>]. In a study on the apigenin effect on NSCLC cells, an inhibition of the migration/invasion via suppressing the Snail/Slug-mediated EMT has been observed. The invasive ability of NSCLC cells was modulated by the suppressive interplay of Akt and Snail/Slug signaling, harboring different EGFR statuses [<xref rid="B32-ijms-20-04291" ref-type="bibr">32</xref>].</p><p>In A549 cells, delphinidin has proved to have a potentially new role in anti-angiogenic action. The inhibitory effects of delphinidin on the vascular endothelial growth factor (VEGF) is due to the suppression of the binding of HIF-1 to the HRE promoter with specifically decreasing the CoCl<sub>2</sub>- and EGF-induced HIF-1&#x003b1; protein expression [<xref rid="B70-ijms-20-04291" ref-type="bibr">70</xref>]. Furthermore, delphinidin was demonstrated to have an inhibitory effect of EGFR and VEGFR2 in lung cancer cells. The biological active properties may be explained by the simultaneous inhibition of the EGFR and VEGFR2 signaling pathways, and by the activation of PI3K/Akt and MAPKs [<xref rid="B71-ijms-20-04291" ref-type="bibr">71</xref>]. In A549 and H1299 cells, baicalein treatment showed it down-regulated Notch1 and hes-1 expression and significantly inhibited the cell invasion and EMT [<xref rid="B72-ijms-20-04291" ref-type="bibr">72</xref>]. In A549 lung cancer cells, EGCG treatment determined TGF&#x003b2;1-mediated EMT inhibition by suppressing the acetylation of Smad2 and Smad3 [<xref rid="B73-ijms-20-04291" ref-type="bibr">73</xref>].</p></sec></sec><sec id="sec4-ijms-20-04291"><title>4. Flavonoids as miRNA Modulators in Lung Cancer</title><p>A non-coding RNA (ncRNA) is a functional RNA molecule that is transcribed from DNA but not translated into proteins [<xref rid="B74-ijms-20-04291" ref-type="bibr">74</xref>,<xref rid="B75-ijms-20-04291" ref-type="bibr">75</xref>]. The noncoding RNAs are involved in many cellular processes, the most important function being to regulate gene expression at the transcriptional and post-transcriptional level [<xref rid="B76-ijms-20-04291" ref-type="bibr">76</xref>,<xref rid="B77-ijms-20-04291" ref-type="bibr">77</xref>,<xref rid="B78-ijms-20-04291" ref-type="bibr">78</xref>]. Many pre-clinical reports have described the opportunity of restoring the expression level for the oncogenic or tumor suppressor transcripts as anticancer therapeutic strategies [<xref rid="B74-ijms-20-04291" ref-type="bibr">74</xref>,<xref rid="B79-ijms-20-04291" ref-type="bibr">79</xref>]. Based on the earlier studies, the utilization of these therapeutic strategies include the inhibition of oncogenic and restoration of the tumor suppressors transcripts. The effects of flavonoids on the modulation of miRNA expression and its connected target genes level on lung cancer are presented in <xref rid="ijms-20-04291-t003" ref-type="table">Table 3</xref>.</p><p>Dietary flavonoids have been demonstrated to have a role as potential immune modulators because of their lack of adverse effects, low cost and easy administration [<xref rid="B62-ijms-20-04291" ref-type="bibr">62</xref>]. The miR-155-inducing signals use the NF&#x003ba;B pathway and regulate the intensity and duration of the immune response [<xref rid="B63-ijms-20-04291" ref-type="bibr">63</xref>]. The miR-155, together with miR-9, miR-21, miR-29a, miR-126, miR-146 were included in the so called inflamma-miRs and have been shown to be involved in various pathologies including cancer [<xref rid="B64-ijms-20-04291" ref-type="bibr">64</xref>,<xref rid="B65-ijms-20-04291" ref-type="bibr">65</xref>] by regulating NFkB signaling. Considering the fact that genistein downregulates the expression of miR155 in breast cancer cells by regulating the miR-155 targets Foxo3, PTEN and p27 expression [<xref rid="B80-ijms-20-04291" ref-type="bibr">80</xref>], the targets found also in lung cancer would be interesting to study in the future regarding modulation of miR-155 by flavonoids in lung adenocarcinoma. miR-155 is a transcript that promote lung cancer progress and was proved to be overexpressed [<xref rid="B58-ijms-20-04291" ref-type="bibr">58</xref>]. Furthermore, miR-155 is one of the most important miRNAs involved in cancer and biological processes, like inflammation [<xref rid="B59-ijms-20-04291" ref-type="bibr">59</xref>]. In NSCLC, miR-155 has been detected to be up-regulated by suggesting an important role as an oncogene and being associated with a poor prognosis [<xref rid="B60-ijms-20-04291" ref-type="bibr">60</xref>,<xref rid="B61-ijms-20-04291" ref-type="bibr">61</xref>].</p><p>The EGCG treatment can adjust miRNAs that play an important role in the MAPK signaling pathway [<xref rid="B81-ijms-20-04291" ref-type="bibr">81</xref>]. The miR-98 is a vital miRNA that was observed to inhibit apoptosis, invasion, proliferation and migration in NSCLC cells through the down-regulation of PAK1 expression [<xref rid="B82-ijms-20-04291" ref-type="bibr">82</xref>]. The miR-98 was found to be downregulated in A549 cells EGCG-treated and increased the efficacy of cisplatin [<xref rid="B83-ijms-20-04291" ref-type="bibr">83</xref>]. The anti-cancer activity of EGCG in lung cancer cells is due to specifically the upregulation of miR-210 which is a major miRNA regulated by HIF-1&#x003b1; [<xref rid="B84-ijms-20-04291" ref-type="bibr">84</xref>]. In the EGCG-treated A549 cells, a lower expression of miR-212 was observed. This indicated the fact that A549 cells are resistant to EGCG treatment [<xref rid="B81-ijms-20-04291" ref-type="bibr">81</xref>].</p><p>MiR-27a was discovered to be an important regulator in many pathological carcinogenesis processes [<xref rid="B2-ijms-20-04291" ref-type="bibr">2</xref>] and can be considered a potential target for lung cancer therapy. TheMiR-27a expression levels were activated through a decrease of the MET protein expression levels in lung cancer cells after genistein treatment [<xref rid="B85-ijms-20-04291" ref-type="bibr">85</xref>]. The overexpression of miR-27a and the reduction of MET protein expression revealed that genistein has anti-cancer effects on lung cancer cells in a dose-dependent manner [<xref rid="B85-ijms-20-04291" ref-type="bibr">85</xref>]. The MiR-27a function as oncogene by regulation of TGF&#x003b2; signaling pathway by targeting SMAD2/4 [<xref rid="B2-ijms-20-04291" ref-type="bibr">2</xref>].</p><p>Another prognostic marker in NSCLC is miR-16 [<xref rid="B86-ijms-20-04291" ref-type="bibr">86</xref>]. miR-16 was demonstrated to regulate the pro-tumorigenic potential of lung fibroblasts [<xref rid="B87-ijms-20-04291" ref-type="bibr">87</xref>]. In lung cancer cells, the decreasing of claudin-2 expression was mediated by the up-regulation of miR-16 expression after quercetin treatment suggesting a flavonoid inhibition effect [<xref rid="B67-ijms-20-04291" ref-type="bibr">67</xref>]. Claudin-2 is connected to the upregulation miR-16 but not of miR-15a, miR-15b, miR-195, miR-424, and miR-497 [<xref rid="B88-ijms-20-04291" ref-type="bibr">88</xref>]. Quercetin did not inhibit the phosphorylated form of ERK1/2 and Akt. However, it has the capacity to reduce the expression of the tight junction protein, claudin-2. The transcriptional activity of claudin-2 is up-regulated by STAT3 [<xref rid="B88-ijms-20-04291" ref-type="bibr">88</xref>]. miR-340 was reported as a novel tumor suppressor in NSCLC [<xref rid="B89-ijms-20-04291" ref-type="bibr">89</xref>]. In A549 cells, kaempferol inhibited proliferation and induced apoptosis and autophagy. Kaempferol treatment up-regulated the expression of miR-340. Therefore, an increase of the PTEN level and the decreasing of p-PI3K and p-Akt levels [<xref rid="B34-ijms-20-04291" ref-type="bibr">34</xref>] was observed.</p></sec><sec id="sec5-ijms-20-04291"><title>5. Flavonoids in Combination with Chemotherapeutic and Radiotherapy Treatment in Lung Cancer</title><p>Several studies have revealed that these compounds have the capacity to potentiate the anticancer potential for most of the cases [<xref rid="B90-ijms-20-04291" ref-type="bibr">90</xref>], supporting normal cells from the secondary effects as a consequence of chemotherapy and radiotherapy [<xref rid="B91-ijms-20-04291" ref-type="bibr">91</xref>]. At the same time, they can modulate the inhibition of key multiple singling pathways activated in cancer which evidently provides important benefits in anticancer treatment [<xref rid="B76-ijms-20-04291" ref-type="bibr">76</xref>,<xref rid="B90-ijms-20-04291" ref-type="bibr">90</xref>]. The standard chemotherapy cytotoxic acts by causing free radicals which can be balanced by natural phytochemicals that have an important role in prevention of this. However, they are mainly used as adjuvant agents. These antioxidant effects can protect from ROS normal cells, but also the tumor cells. This can be two-edged. In some cases, a positive effect has been observed. However, in other cases, this can be related to the diminution in the effectiveness of cytotoxic therapy which is difficult to demonstrate and subtract beyond the side effects observed from chemotherapeutic treatment and radiotherapy [<xref rid="B91-ijms-20-04291" ref-type="bibr">91</xref>,<xref rid="B92-ijms-20-04291" ref-type="bibr">92</xref>]. The beneficial effects of flavonoids, in combination with chemotherapeutic and radiotherapy treatment in lung cancer, are presented in <xref rid="ijms-20-04291-t004" ref-type="table">Table 4</xref>.</p><p>In the NSCLC cell lines, EGCG acts as an adjuvant to combat cDDP resistance by EGCG-mediated CTR1 mechanism via NEAT1/mir-98-5p crosstalk [<xref rid="B93-ijms-20-04291" ref-type="bibr">93</xref>]. In NSCLC cells after treatment with combination of metformin and EGCG, it has been observed that metformin sensitized to the EGCG treatment by suppressing the Nrf2/HO-1 signaling pathway [<xref rid="B94-ijms-20-04291" ref-type="bibr">94</xref>].</p><p>Quercetin enhances the sensitivity to gemcitabine treatment in lung adenocarcinoma by increasing cells apoptosis via inhibiting HSP70 expression [<xref rid="B95-ijms-20-04291" ref-type="bibr">95</xref>]. Simultaneous treatment of resveratrol and clofarabine induced apoptosis in H-2452 cells by reducing Mcl-1 protein level [<xref rid="B96-ijms-20-04291" ref-type="bibr">96</xref>]. Co-treatment with resveratrol and erlotinib on lung cancer cells inhibited the Akt/mTOR/S6 kinase pathway enhanced the anti-tumor effects of erlotinib and repressed the expressions of anti-apoptosis proteins [<xref rid="B97-ijms-20-04291" ref-type="bibr">97</xref>]. In chemoresistant lung cancer cells, EGCG induces the reversion of cisplatin resistance mediated by downregulation of AXK and TYRO3 receptor tyrosine kinases. After combination treatment with honokiol and cetuximab in non-small cell lung cancer H226 cell line has been observed a downregulation of HER family and their signaling pathways [<xref rid="B98-ijms-20-04291" ref-type="bibr">98</xref>].</p><p>In lung cancer cells, a combination treatment of quercertin and gemcitabine had significant antiproliferative and pro-apoptotic activities by the downregulation of the HSP70 expression [<xref rid="B95-ijms-20-04291" ref-type="bibr">95</xref>]. After the combined treatment of fisetin with paclitaxel in the A549 cells, a relation between the autophagic and apoptotic cell death has not been observed as the percentage of the apoptotic cells did not increase significantly [<xref rid="B99-ijms-20-04291" ref-type="bibr">99</xref>]. Since radiotherapy is one of the prime treatment measures for lung cancer, the need to enhance radiotherapy efficacy and protect normal tissues has appeared. The Bcl-xL pathway inhibition has been demonstrated to improve the resistance to radiotherapy in lung cancer patients [<xref rid="B100-ijms-20-04291" ref-type="bibr">100</xref>]. Genistein treatment increased the radiosensitivity of lung cancer cells through stimulating apoptosis due to the reducing plasmic Bcl-xL levels [<xref rid="B101-ijms-20-04291" ref-type="bibr">101</xref>]. Baicalein increased the sensitivity of cisplatin in lung cancer cells via the PI3K/Akt/NF&#x003ba;B pathway mediated-EMT [<xref rid="B102-ijms-20-04291" ref-type="bibr">102</xref>]. The combined treatment of diosmetin and paclitaxel synergistically suppressed lung cancer cells via ROS accumulation through the PI3K/Akt/GSK-3&#x003b2;/Nrf2 pathway disruption [<xref rid="B103-ijms-20-04291" ref-type="bibr">103</xref>].</p></sec><sec sec-type="conclusions" id="sec6-ijms-20-04291"><title>6. Conclusions and Perspectives</title><p>Flavonoids have received much attention, as demonstrated by the high number of papers published in the last years. Novel mechanistic insights have been demonstrated in cancer therapy where most of the beneficial effects have altered oncogenic signaling, including lung cancer.</p><p>The flavonoids discussed in this article inhibited lung carcinogenesis in preclinical studies and have the capacity to target signaling pathways. However, there are many limitations for their use in clinical trials which explains the lack of the data from clinical trials. The main cause is the lack of biomarkers and gaps in our comprehension of the pathogenesis of lung cancer along with lack of good models for risk prediction.</p><p>Therefore, a combination of these agents would be more helpful to be used in future clinical trials. For a successful therapy, it would be more reasonable to use the different combined scenarios of therapeutic agents and flavonoids, while also decreasing the dose of chemotherapeutics resulting a decreased in toxicity and providing a maximum efficacy by targeting multiple signaling pathways.</p><p>A thorough comprehension of the association between the different functional groups within the structures of flavonoids and their impact on molecular mechanism is vital for the additional advancement and modification of the basic structure of flavonoids in order to increase their therapeutic efficacy. This knowledge will aid in the development of improved therapeutic strategies for the prevention and treatment of solid tumors, including lung cancer. However, there are still many challenges related to the effect of flavonoids, considering the lack of the epidemiological data even though they were proved to have remarkable and beneficial pharmacological effects.</p></sec></body><back><notes><title>Author Contributions</title><p>O.Z. conceptualization and draft preparation, C.B., A.J. and A.R. methodology and data curation; R.B. and I.B.-N. review and editing. All the authors contributed on the writing of the manuscript.</p></notes><notes><title>Funding</title><p>This research was funded by a POC grant; entitled &#x0201c;Clinical and economical impact of personalized targeted anti-microRNA therapies in reconverting lung cancer chemoresistance&#x0201d;&#x02014;CANTEMIR (contract number 35/01.09.2016). Also this paper was part of PNCDI III 2015-2020 &#x0201c;Increasing the performance of scientific research and technology transfer in translational medicine through the formation of a new generation of young researchers&#x0201d; &#x02013; ECHITAS, no. 29PFE/ 18.10. 2018 and project CNFIS-FDI (CNFIS-FDI-2019-0666), entitled &#x0201c;Sustenance and valorification of research of excellence in the domain of personalized medicine by internationalization and increasement of research activities visibility&#x0201d;.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-ijms-20-04291"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allemani</surname><given-names>C.</given-names></name><name><surname>Weir</surname><given-names>H.K.</given-names></name><name><surname>Carreira</surname><given-names>H.</given-names></name><name><surname>Harewood</surname><given-names>R.</given-names></name><name><surname>Spika</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>X.S.</given-names></name><name><surname>Bannon</surname><given-names>F.</given-names></name><name><surname>Ahn</surname><given-names>J.V.</given-names></name><name><surname>Johnson</surname><given-names>C.J.</given-names></name><name><surname>Bonaventure</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Global surveillance of cancer survival 1995&#x02013;2009: Analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (concord-2)</article-title><source>Lancet</source><year>2015</year><volume>385</volume><fpage>977</fpage><lpage>1010</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(14)62038-9</pub-id><pub-id pub-id-type="pmid">25467588</pub-id></element-citation></ref><ref id="B2-ijms-20-04291"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chae</surname><given-names>D.K.</given-names></name><name><surname>Ban</surname><given-names>E.</given-names></name><name><surname>Yoo</surname><given-names>Y.S.</given-names></name><name><surname>Kim</surname><given-names>E.E.</given-names></name><name><surname>Baik</surname><given-names>J.H.</given-names></name><name><surname>Song</surname><given-names>E.J.</given-names></name></person-group><article-title>Mir-27a regulates the tgf-beta signaling pathway by targeting smad2 and smad4 in lung cancer</article-title><source>Mol. Carcinog.</source><year>2017</year><volume>56</volume><fpage>1992</fpage><lpage>1998</lpage><pub-id pub-id-type="doi">10.1002/mc.22655</pub-id><?supplied-pmid 28370334?><pub-id pub-id-type="pmid">28370334</pub-id></element-citation></ref><ref id="B3-ijms-20-04291"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>F.</given-names></name><name><surname>Ferlay</surname><given-names>J.</given-names></name><name><surname>Soerjomataram</surname><given-names>I.</given-names></name><name><surname>Siegel</surname><given-names>R.L.</given-names></name><name><surname>Torre</surname><given-names>L.A.</given-names></name><name><surname>Jemal</surname><given-names>A.</given-names></name></person-group><article-title>Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J. Clin.</source><year>2018</year><volume>68</volume><fpage>394</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.3322/caac.21492</pub-id><?supplied-pmid 30207593?><pub-id pub-id-type="pmid">30207593</pub-id></element-citation></ref><ref id="B4-ijms-20-04291"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altorki</surname><given-names>N.K.</given-names></name><name><surname>Markowitz</surname><given-names>G.J.</given-names></name><name><surname>Gao</surname><given-names>D.</given-names></name><name><surname>Port</surname><given-names>J.L.</given-names></name><name><surname>Saxena</surname><given-names>A.</given-names></name><name><surname>Stiles</surname><given-names>B.</given-names></name><name><surname>McGraw</surname><given-names>T.</given-names></name><name><surname>Mittal</surname><given-names>V.</given-names></name></person-group><article-title>The lung microenvironment: An important regulator of tumour growth and metastasis</article-title><source>Nat. Rev. Cancer</source><year>2019</year><volume>19</volume><fpage>9</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1038/s41568-018-0081-9</pub-id><?supplied-pmid 30532012?><pub-id pub-id-type="pmid">30532012</pub-id></element-citation></ref><ref id="B5-ijms-20-04291"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>T.</given-names></name><name><surname>Tateishi</surname><given-names>A.</given-names></name><name><surname>Bychkov</surname><given-names>A.</given-names></name><name><surname>Fukuoka</surname><given-names>J.</given-names></name></person-group><article-title>Remarkable alteration of pd-l1 expression after immune checkpoint therapy in patients with non-small-cell lung cancer: Two autopsy case reports</article-title><source>Int. J. Mol. Sci.</source><year>2019</year><volume>20</volume><elocation-id>2578</elocation-id><pub-id pub-id-type="doi">10.3390/ijms20102578</pub-id><?supplied-pmid 31130676?><pub-id pub-id-type="pmid">31130676</pub-id></element-citation></ref><ref id="B6-ijms-20-04291"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vigneswaran</surname><given-names>J.</given-names></name><name><surname>Tan</surname><given-names>Y.H.</given-names></name><name><surname>Murgu</surname><given-names>S.D.</given-names></name><name><surname>Won</surname><given-names>B.M.</given-names></name><name><surname>Patton</surname><given-names>K.A.</given-names></name><name><surname>Villaflor</surname><given-names>V.M.</given-names></name><name><surname>Hoffman</surname><given-names>P.C.</given-names></name><name><surname>Hensing</surname><given-names>T.</given-names></name><name><surname>Hogarth</surname><given-names>D.K.</given-names></name><name><surname>Malik</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>18876</fpage><lpage>18886</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.7739</pub-id><?supplied-pmid 26934441?><pub-id pub-id-type="pmid">26934441</pub-id></element-citation></ref><ref id="B7-ijms-20-04291"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>S.J.</given-names></name><name><surname>More</surname><given-names>S.</given-names></name><name><surname>Murtuza</surname><given-names>A.</given-names></name><name><surname>Woodward</surname><given-names>B.D.</given-names></name><name><surname>Husain</surname><given-names>H.</given-names></name></person-group><article-title>New targets in non&#x02013;small cell lung cancer</article-title><source>Hematol. Oncol. Clin. N. Am.</source><year>2017</year><volume>31</volume><fpage>113</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.hoc.2016.08.010</pub-id><?supplied-pmid 27912827?><pub-id pub-id-type="pmid">27912827</pub-id></element-citation></ref><ref id="B8-ijms-20-04291"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snyder-Talkington</surname><given-names>B.N.</given-names></name><name><surname>Dong</surname><given-names>C.</given-names></name><name><surname>Singh</surname><given-names>S.</given-names></name><name><surname>Raese</surname><given-names>R.</given-names></name><name><surname>Qian</surname><given-names>Y.</given-names></name><name><surname>Porter</surname><given-names>D.W.</given-names></name><name><surname>Wolfarth</surname><given-names>M.G.</given-names></name><name><surname>Guo</surname><given-names>N.L.</given-names></name></person-group><article-title>Multi-walled carbon nanotube-induced gene expression biomarkers for medical and occupational surveillance</article-title><source>Int. J. Mol. Sci.</source><year>2019</year><volume>20</volume><elocation-id>2635</elocation-id><pub-id pub-id-type="doi">10.3390/ijms20112635</pub-id><?supplied-pmid 31146342?><pub-id pub-id-type="pmid">31146342</pub-id></element-citation></ref><ref id="B9-ijms-20-04291"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shivappa</surname><given-names>N.</given-names></name><name><surname>Wang</surname><given-names>R.</given-names></name><name><surname>Hebert</surname><given-names>J.R.</given-names></name><name><surname>Jin</surname><given-names>A.</given-names></name><name><surname>Koh</surname><given-names>W.P.</given-names></name><name><surname>Yuan</surname><given-names>J.M.</given-names></name></person-group><article-title>Association between inflammatory potential of diet and risk of lung cancer among smokers in a prospective study in singapore</article-title><source>Eur. J. Nutr.</source><year>2018</year><pub-id pub-id-type="doi">10.1007/s00394-018-1825-8</pub-id><?supplied-pmid 30255403?><pub-id pub-id-type="pmid">30255403</pub-id></element-citation></ref><ref id="B10-ijms-20-04291"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krusinska</surname><given-names>B.</given-names></name><name><surname>Hawrysz</surname><given-names>I.</given-names></name><name><surname>Wadolowska</surname><given-names>L.</given-names></name><name><surname>Slowinska</surname><given-names>M.A.</given-names></name><name><surname>Biernacki</surname><given-names>M.</given-names></name><name><surname>Czerwinska</surname><given-names>A.</given-names></name><name><surname>Golota</surname><given-names>J.J.</given-names></name></person-group><article-title>Associations of mediterranean diet and a posteriori derived dietary patterns with breast and lung cancer risk: A case-control study</article-title><source>Nutrients</source><year>2018</year><volume>10</volume><elocation-id>470</elocation-id><pub-id pub-id-type="doi">10.3390/nu10040470</pub-id><?supplied-pmid 29641468?><pub-id pub-id-type="pmid">29641468</pub-id></element-citation></ref><ref id="B11-ijms-20-04291"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vauzour</surname><given-names>D.</given-names></name><name><surname>Rodriguez-Mateos</surname><given-names>A.</given-names></name><name><surname>Corona</surname><given-names>G.</given-names></name><name><surname>Oruna-Concha</surname><given-names>M.J.</given-names></name><name><surname>Spencer</surname><given-names>J.P.</given-names></name></person-group><article-title>Polyphenols and human health: Prevention of disease and mechanisms of action</article-title><source>Nutrients</source><year>2010</year><volume>2</volume><fpage>1106</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.3390/nu2111106</pub-id><?supplied-pmid 22254000?><pub-id pub-id-type="pmid">22254000</pub-id></element-citation></ref><ref id="B12-ijms-20-04291"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Budisan</surname><given-names>L.</given-names></name><name><surname>Gulei</surname><given-names>D.</given-names></name><name><surname>Zanoaga</surname><given-names>O.M.</given-names></name><name><surname>Irimie</surname><given-names>A.I.</given-names></name><name><surname>Sergiu</surname><given-names>C.</given-names></name><name><surname>Braicu</surname><given-names>C.</given-names></name><name><surname>Gherman</surname><given-names>C.D.</given-names></name><name><surname>Berindan-Neagoe</surname><given-names>I.</given-names></name></person-group><article-title>Dietary intervention by phytochemicals and their role in modulating coding and non-coding genes in cancer</article-title><source>Int. J. Mol. Sci.</source><year>2017</year><volume>18</volume><elocation-id>1178</elocation-id><pub-id pub-id-type="doi">10.3390/ijms18061178</pub-id><?supplied-pmid 28587155?><pub-id pub-id-type="pmid">28587155</pub-id></element-citation></ref><ref id="B13-ijms-20-04291"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>C.Y.</given-names></name><name><surname>Yen</surname><given-names>H.</given-names></name><name><surname>Hsiao</surname><given-names>H.Y.</given-names></name><name><surname>Su</surname><given-names>S.C.</given-names></name></person-group><article-title>Phytochemicals in skin cancer prevention and treatment: An updated review</article-title><source>Int. J. Mol. Sci.</source><year>2018</year><volume>19</volume><elocation-id>941</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19040941</pub-id><?supplied-pmid 29565284?><pub-id pub-id-type="pmid">29565284</pub-id></element-citation></ref><ref id="B14-ijms-20-04291"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cojocneanu Petric</surname><given-names>R.</given-names></name><name><surname>Braicu</surname><given-names>C.</given-names></name><name><surname>Raduly</surname><given-names>L.</given-names></name><name><surname>Zanoaga</surname><given-names>O.</given-names></name><name><surname>Dragos</surname><given-names>N.</given-names></name><name><surname>Monroig</surname><given-names>P.</given-names></name><name><surname>Dumitrascu</surname><given-names>D.</given-names></name><name><surname>Berindan-Neagoe</surname><given-names>I.</given-names></name></person-group><article-title>Phytochemicals modulate carcinogenic signaling pathways in breast and hormone-related cancers</article-title><source>Oncotargets Ther.</source><year>2015</year><volume>8</volume><fpage>2053</fpage><lpage>2066</lpage><pub-id pub-id-type="doi">10.2147/OTT.S83597</pub-id><?supplied-pmid 26273208?><pub-id pub-id-type="pmid">26273208</pub-id></element-citation></ref><ref id="B15-ijms-20-04291"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chahar</surname><given-names>M.K.</given-names></name><name><surname>Sharma</surname><given-names>N.</given-names></name><name><surname>Dobhal</surname><given-names>M.P.</given-names></name><name><surname>Joshi</surname><given-names>Y.C.</given-names></name></person-group><article-title>Flavonoids: A versatile source of anticancer drugs</article-title><source>Pharmacogn. Rev.</source><year>2011</year><volume>5</volume><fpage>1</fpage><lpage>12</lpage><?supplied-pmid 22096313?><pub-id pub-id-type="pmid">22096313</pub-id></element-citation></ref><ref id="B16-ijms-20-04291"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braicu</surname><given-names>C.</given-names></name><name><surname>Pilecki</surname><given-names>V.</given-names></name><name><surname>Balacescu</surname><given-names>O.</given-names></name><name><surname>Irimie</surname><given-names>A.</given-names></name><name><surname>Neagoe</surname><given-names>I.B.</given-names></name></person-group><article-title>The relationships between biological activities and structure of flavan-3-ols</article-title><source>Int. J. Mol. Sci.</source><year>2011</year><volume>12</volume><fpage>9342</fpage><lpage>9353</lpage><pub-id pub-id-type="doi">10.3390/ijms12129342</pub-id><?supplied-pmid 22272136?><pub-id pub-id-type="pmid">22272136</pub-id></element-citation></ref><ref id="B17-ijms-20-04291"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batra</surname><given-names>P.</given-names></name><name><surname>Sharma</surname><given-names>A.K.</given-names></name></person-group><article-title>Anti-cancer potential of flavonoids: Recent trends and future perspectives</article-title><source>3 Biotech</source><year>2013</year><volume>3</volume><fpage>439</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1007/s13205-013-0117-5</pub-id><?supplied-pmid 28324424?><pub-id pub-id-type="pmid">28324424</pub-id></element-citation></ref><ref id="B18-ijms-20-04291"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Budisan</surname><given-names>L.</given-names></name><name><surname>Gulei</surname><given-names>D.</given-names></name><name><surname>Jurj</surname><given-names>A.</given-names></name><name><surname>Braicu</surname><given-names>C.</given-names></name><name><surname>Zanoaga</surname><given-names>O.</given-names></name><name><surname>Cojocneanu</surname><given-names>R.</given-names></name><name><surname>Pop</surname><given-names>L.</given-names></name><name><surname>Raduly</surname><given-names>L.</given-names></name><name><surname>Barbat</surname><given-names>A.</given-names></name><name><surname>Moldovan</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Inhibitory effect of cape and kaempferol in colon cancer cell lines-possible implications in new therapeutic strategies</article-title><source>Int. J. Mol. Sci.</source><year>2019</year><volume>20</volume><elocation-id>1199</elocation-id><pub-id pub-id-type="doi">10.3390/ijms20051199</pub-id></element-citation></ref><ref id="B19-ijms-20-04291"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>T.</given-names></name><name><surname>Wu</surname><given-names>D.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Ye</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Cao</surname><given-names>Z.</given-names></name><name><surname>Tang</surname><given-names>K.</given-names></name></person-group><article-title>Exploring the mechanism of flavonoids through systematic bioinformatics analysis</article-title><source>Front. Pharmacol.</source><year>2018</year><volume>9</volume><fpage>918</fpage><pub-id pub-id-type="doi">10.3389/fphar.2018.00918</pub-id><?supplied-pmid 30158870?><pub-id pub-id-type="pmid">30158870</pub-id></element-citation></ref><ref id="B20-ijms-20-04291"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>T.</given-names></name><name><surname>Chen</surname><given-names>G.Y.</given-names></name></person-group><article-title>Flavonoids and colorectal cancer prevention</article-title><source>Antioxidant</source><year>2018</year><volume>7</volume><elocation-id>187</elocation-id><pub-id pub-id-type="doi">10.3390/antiox7120187</pub-id></element-citation></ref><ref id="B21-ijms-20-04291"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>S.Y.</given-names></name><name><surname>Lee</surname><given-names>Y.</given-names></name><name><surname>Kim</surname><given-names>B.S.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Ahn</surname><given-names>S.</given-names></name><name><surname>Koh</surname><given-names>D.</given-names></name><name><surname>Lim</surname><given-names>Y.</given-names></name><name><surname>Lee</surname><given-names>Y.H.</given-names></name></person-group><article-title>Inhibitory effect of synthetic flavone derivatives on pan-aurora kinases: Induction of g2/m cell-cycle arrest and apoptosis in hct116 human colon cancer cells</article-title><source>Int. J. Mol. Sci.</source><year>2018</year><volume>19</volume><elocation-id>4086</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19124086</pub-id><?supplied-pmid 30562979?><pub-id pub-id-type="pmid">30562979</pub-id></element-citation></ref><ref id="B22-ijms-20-04291"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanwal</surname><given-names>R.</given-names></name><name><surname>Datt</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Gupta</surname><given-names>S.</given-names></name></person-group><article-title>Dietary flavones as dual inhibitors of DNA methyltransferases and histone methyltransferases</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0162956</elocation-id><pub-id pub-id-type="pmid">27658199</pub-id></element-citation></ref><ref id="B23-ijms-20-04291"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xingyu</surname><given-names>Z.</given-names></name><name><surname>Peijie</surname><given-names>M.</given-names></name><name><surname>Dan</surname><given-names>P.</given-names></name><name><surname>Youg</surname><given-names>W.</given-names></name><name><surname>Daojun</surname><given-names>W.</given-names></name><name><surname>Xinzheng</surname><given-names>C.</given-names></name><name><surname>Xijun</surname><given-names>Z.</given-names></name><name><surname>Yangrong</surname><given-names>S.</given-names></name></person-group><article-title>Quercetin suppresses lung cancer growth by targeting aurora b kinase</article-title><source>Cancer Med.</source><year>2016</year><volume>5</volume><fpage>3156</fpage><lpage>3165</lpage><pub-id pub-id-type="doi">10.1002/cam4.891</pub-id><?supplied-pmid 27704720?><pub-id pub-id-type="pmid">27704720</pub-id></element-citation></ref><ref id="B24-ijms-20-04291"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonoki</surname><given-names>H.</given-names></name><name><surname>Tanimae</surname><given-names>A.</given-names></name><name><surname>Endo</surname><given-names>S.</given-names></name><name><surname>Matsunaga</surname><given-names>T.</given-names></name><name><surname>Furuta</surname><given-names>T.</given-names></name><name><surname>Ichihara</surname><given-names>K.</given-names></name><name><surname>Ikari</surname><given-names>A.</given-names></name></person-group><article-title>Kaempherol and luteolin decrease claudin-2 expression mediated by inhibition of stat3 in lung adenocarcinoma a549 cells</article-title><source>Nutrients</source><year>2017</year><volume>9</volume><elocation-id>597</elocation-id><pub-id pub-id-type="doi">10.3390/nu9060597</pub-id><?supplied-pmid 28608828?><pub-id pub-id-type="pmid">28608828</pub-id></element-citation></ref><ref id="B25-ijms-20-04291"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>G.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Zheng</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Chen</surname><given-names>Q.-H.</given-names></name></person-group><article-title>A new class of flavonol-based anti-prostate cancer agents: Design, synthesis, and evaluation in cell models</article-title><source>Bioorganic Med. Chem. Lett.</source><year>2016</year><volume>26</volume><fpage>4241</fpage><lpage>4245</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2016.07.050</pub-id><?supplied-pmid 27476422?><pub-id pub-id-type="pmid">27476422</pub-id></element-citation></ref><ref id="B26-ijms-20-04291"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chanet</surname><given-names>A.</given-names></name><name><surname>Milenkovic</surname><given-names>D.</given-names></name><name><surname>Manach</surname><given-names>C.</given-names></name><name><surname>Mazur</surname><given-names>A.</given-names></name><name><surname>Morand</surname><given-names>C.</given-names></name></person-group><article-title>Citrus flavanones: What is their role in cardiovascular protection?</article-title><source>J. Agric. Food Chem.</source><year>2012</year><volume>60</volume><fpage>8809</fpage><lpage>8822</lpage><pub-id pub-id-type="doi">10.1021/jf300669s</pub-id><?supplied-pmid 22574825?><pub-id pub-id-type="pmid">22574825</pub-id></element-citation></ref><ref id="B27-ijms-20-04291"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>Y.</given-names></name><name><surname>Shin</surname><given-names>S.Y.</given-names></name><name><surname>Hyun</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>S.D.</given-names></name><name><surname>Lee</surname><given-names>Y.H.</given-names></name><name><surname>Lim</surname><given-names>Y.</given-names></name></person-group><article-title>Flavanones inhibit the clonogenicity of hct116 cololectal cancer cells</article-title><source>Int. J. Mol. Med.</source><year>2012</year><volume>29</volume><fpage>403</fpage><lpage>408</lpage><?supplied-pmid 22160193?><pub-id pub-id-type="pmid">22160193</pub-id></element-citation></ref><ref id="B28-ijms-20-04291"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abotaleb</surname><given-names>M.</given-names></name><name><surname>Samuel</surname><given-names>S.M.</given-names></name><name><surname>Varghese</surname><given-names>E.</given-names></name><name><surname>Varghese</surname><given-names>S.</given-names></name><name><surname>Kubatka</surname><given-names>P.</given-names></name><name><surname>Liskova</surname><given-names>A.</given-names></name><name><surname>B&#x000fc;sselberg</surname><given-names>D.</given-names></name></person-group><article-title>Flavonoids in cancer and apoptosis</article-title><source>Cancers</source><year>2018</year><volume>11</volume><elocation-id>28</elocation-id><pub-id pub-id-type="doi">10.3390/cancers11010028</pub-id><?supplied-pmid 30597838?><pub-id pub-id-type="pmid">30597838</pub-id></element-citation></ref><ref id="B29-ijms-20-04291"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>H.-J.</given-names></name><name><surname>Hwang</surname><given-names>K.-A.</given-names></name><name><surname>Choi</surname><given-names>K.-C.</given-names></name></person-group><article-title>Antitumor effect of various phytochemicals on diverse types of thyroid cancers</article-title><source>Nutrients</source><year>2019</year><volume>11</volume><elocation-id>125</elocation-id><pub-id pub-id-type="doi">10.3390/nu11010125</pub-id><?supplied-pmid 30634497?><pub-id pub-id-type="pmid">30634497</pub-id></element-citation></ref><ref id="B30-ijms-20-04291"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Sousa Moraes</surname><given-names>L.F.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Peluzio</surname><given-names>M.</given-names></name><name><surname>Zhu</surname><given-names>M.J.</given-names></name></person-group><article-title>Anthocyanins/anthocyanidins and colorectal cancer: What is behind the scenes?</article-title><source>Crit. Rev. Food Sci. Nutr.</source><year>2019</year><volume>59</volume><fpage>59</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1080/10408398.2017.1357533</pub-id><?supplied-pmid 28799785?><pub-id pub-id-type="pmid">28799785</pub-id></element-citation></ref><ref id="B31-ijms-20-04291"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Z.</given-names></name><name><surname>Tang</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Lu</surname><given-names>R.</given-names></name><name><surname>Lu</surname><given-names>J.</given-names></name></person-group><article-title>Apigenin inhibits cell proliferation, migration, and invasion by targeting akt in the a549 human lung cancer cell line</article-title><source>Anti-Cancer Drugs</source><year>2017</year><volume>28</volume><fpage>446</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1097/CAD.0000000000000479</pub-id><?supplied-pmid 28125432?><pub-id pub-id-type="pmid">28125432</pub-id></element-citation></ref><ref id="B32-ijms-20-04291"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>J.H.</given-names></name><name><surname>Cheng</surname><given-names>C.W.</given-names></name><name><surname>Yang</surname><given-names>Y.C.</given-names></name><name><surname>Chen</surname><given-names>W.S.</given-names></name><name><surname>Hung</surname><given-names>W.Y.</given-names></name><name><surname>Chow</surname><given-names>J.M.</given-names></name><name><surname>Chen</surname><given-names>P.S.</given-names></name><name><surname>Hsiao</surname><given-names>M.</given-names></name><name><surname>Lee</surname><given-names>W.J.</given-names></name><name><surname>Chien</surname><given-names>M.H.</given-names></name></person-group><article-title>Downregulating cd26/dppiv by apigenin modulates the interplay between akt and snail/slug signaling to restrain metastasis of lung cancer with multiple egfr statuses</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2018</year><volume>37</volume><fpage>199</fpage><pub-id pub-id-type="doi">10.1186/s13046-018-0869-1</pub-id><?supplied-pmid 30134935?><pub-id pub-id-type="pmid">30134935</pub-id></element-citation></ref><ref id="B33-ijms-20-04291"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>H.J.</given-names></name><name><surname>Ahn</surname><given-names>K.C.</given-names></name><name><surname>Choi</surname><given-names>J.Y.</given-names></name><name><surname>Hwang</surname><given-names>S.G.</given-names></name><name><surname>Kim</surname><given-names>W.J.</given-names></name><name><surname>Um</surname><given-names>H.D.</given-names></name><name><surname>Park</surname><given-names>J.K.</given-names></name></person-group><article-title>Luteolin acts as a radiosensitizer in nonsmall cell lung cancer cells by enhancing apoptotic cell death through activation of a p38/ros/caspase cascade</article-title><source>Int. J. Oncol.</source><year>2015</year><volume>46</volume><fpage>1149</fpage><lpage>1158</lpage><pub-id pub-id-type="doi">10.3892/ijo.2015.2831</pub-id><?supplied-pmid 25586525?><pub-id pub-id-type="pmid">25586525</pub-id></element-citation></ref><ref id="B34-ijms-20-04291"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>C.F.</given-names></name><name><surname>Gao</surname><given-names>N.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name></person-group><article-title>Kaempferol suppresses proliferation but increases apoptosis and autophagy by up-regulating microrna-340 in human lung cancer cells</article-title><source>Biomed. Pharmacother.</source><year>2018</year><volume>108</volume><fpage>809</fpage><lpage>816</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2018.09.087</pub-id><?supplied-pmid 30253373?><pub-id pub-id-type="pmid">30253373</pub-id></element-citation></ref><ref id="B35-ijms-20-04291"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>R.</given-names></name><name><surname>Sheng</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>C.</given-names></name><name><surname>Lu</surname><given-names>H.</given-names></name></person-group><article-title>Hesperidin induces apoptosis and g0/g1 arrest in human non-small cell lung cancer a549 cells</article-title><source>Int. J. Mol. Med.</source><year>2018</year><volume>41</volume><fpage>464</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2017.3250</pub-id><?supplied-pmid 29138795?><pub-id pub-id-type="pmid">29138795</pub-id></element-citation></ref><ref id="B36-ijms-20-04291"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L.C.</given-names></name><name><surname>Tsao</surname><given-names>T.C.</given-names></name><name><surname>Hsu</surname><given-names>S.R.</given-names></name><name><surname>Wang</surname><given-names>H.C.</given-names></name><name><surname>Tsai</surname><given-names>T.C.</given-names></name><name><surname>Kao</surname><given-names>J.Y.</given-names></name><name><surname>Way</surname><given-names>T.D.</given-names></name></person-group><article-title>Egcg inhibits transforming growth factor-beta-mediated epithelial-to-mesenchymal transition via the inhibition of smad2 and erk1/2 signaling pathways in nonsmall cell lung cancer cells</article-title><source>J. Agric. Food Chem.</source><year>2012</year><volume>60</volume><fpage>9863</fpage><lpage>9873</lpage><pub-id pub-id-type="doi">10.1021/jf303690x</pub-id><?supplied-pmid 22957988?><pub-id pub-id-type="pmid">22957988</pub-id></element-citation></ref><ref id="B37-ijms-20-04291"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>T.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Ma</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name></person-group><article-title>Genistein exhibits anti-cancer effects via down-regulating foxm1 in h446 small-cell lung cancer cells</article-title><source>Tumour Biol.</source><year>2014</year><volume>35</volume><fpage>4137</fpage><lpage>4145</lpage><pub-id pub-id-type="doi">10.1007/s13277-013-1542-0</pub-id><?supplied-pmid 24379139?><pub-id pub-id-type="pmid">24379139</pub-id></element-citation></ref><ref id="B38-ijms-20-04291"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>N.</given-names></name><name><surname>Mukhtar</surname><given-names>H.</given-names></name></person-group><article-title>Dietary agents for prevention and treatment of lung cancer</article-title><source>Cancer Lett.</source><year>2015</year><volume>359</volume><fpage>155</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2015.01.038</pub-id><?supplied-pmid 25644088?><pub-id pub-id-type="pmid">25644088</pub-id></element-citation></ref><ref id="B39-ijms-20-04291"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braicu</surname><given-names>C.</given-names></name><name><surname>Mehterov</surname><given-names>N.</given-names></name><name><surname>Vladimirov</surname><given-names>B.</given-names></name><name><surname>Sarafian</surname><given-names>V.</given-names></name><name><surname>Nabavi</surname><given-names>S.M.</given-names></name><name><surname>Atanasov</surname><given-names>A.G.</given-names></name><name><surname>Berindan-Neagoe</surname><given-names>I.</given-names></name></person-group><article-title>Nutrigenomics in cancer: Revisiting the effects of natural compounds</article-title><source>Semin. Cancer Biol.</source><year>2017</year><volume>46</volume><fpage>84</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2017.06.011</pub-id><pub-id pub-id-type="pmid">28676460</pub-id></element-citation></ref><ref id="B40-ijms-20-04291"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>D.X.</given-names></name><name><surname>Kumamoto</surname><given-names>T.</given-names></name></person-group><article-title>Flavonoids as protein kinase inhibitors for cancer chemoprevention: Direct binding and molecular modeling</article-title><source>Antioxid. Redox Signal.</source><year>2010</year><volume>13</volume><fpage>691</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.1089/ars.2009.2816</pub-id><pub-id pub-id-type="pmid">20070239</pub-id></element-citation></ref><ref id="B41-ijms-20-04291"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Regad</surname><given-names>T.</given-names></name></person-group><article-title>Targeting rtk signaling pathways in cancer</article-title><source>Cancers</source><year>2015</year><volume>7</volume><fpage>1758</fpage><lpage>1784</lpage><pub-id pub-id-type="doi">10.3390/cancers7030860</pub-id><?supplied-pmid 26404379?><pub-id pub-id-type="pmid">26404379</pub-id></element-citation></ref><ref id="B42-ijms-20-04291"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W.L.</given-names></name><name><surname>Zhao</surname><given-names>Y.N.</given-names></name><name><surname>Shi</surname><given-names>Z.Z.</given-names></name><name><surname>Cong</surname><given-names>D.</given-names></name><name><surname>Bai</surname><given-names>Y.S.</given-names></name></person-group><article-title>Lutein inhibits cell growth and activates apoptosis via the pi3k/akt/mtor signaling pathway in a549 human non-small-cell lung cancer cells</article-title><source>J. Environ. Pathol. Toxicol. Oncol.</source><year>2018</year><volume>37</volume><fpage>341</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1615/JEnvironPatholToxicolOncol.2018027418</pub-id><?supplied-pmid 30806240?><pub-id pub-id-type="pmid">30806240</pub-id></element-citation></ref><ref id="B43-ijms-20-04291"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shanmugam</surname><given-names>M.K.</given-names></name><name><surname>Lee</surname><given-names>J.H.</given-names></name><name><surname>Chai</surname><given-names>E.Z.P.</given-names></name><name><surname>Kanchi</surname><given-names>M.M.</given-names></name><name><surname>Kar</surname><given-names>S.</given-names></name><name><surname>Arfuso</surname><given-names>F.</given-names></name><name><surname>Dharmarajan</surname><given-names>A.</given-names></name><name><surname>Kumar</surname><given-names>A.P.</given-names></name><name><surname>Ramar</surname><given-names>P.S.</given-names></name><name><surname>Looi</surname><given-names>C.Y.</given-names></name><etal/></person-group><article-title>Cancer prevention and therapy through the modulation of transcription factors by bioactive natural compounds</article-title><source>Semin. Cancer Biol.</source><year>2016</year><volume>40&#x02013;41</volume><fpage>35</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2016.03.005</pub-id><?supplied-pmid 27038646?><pub-id pub-id-type="pmid">27038646</pub-id></element-citation></ref><ref id="B44-ijms-20-04291"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>H.-H.</given-names></name><name><surname>Chu</surname><given-names>J.-H.</given-names></name><name><surname>Kwan</surname><given-names>H.-Y.</given-names></name><name><surname>Su</surname><given-names>T.</given-names></name><name><surname>Yu</surname><given-names>H.</given-names></name><name><surname>Cheng</surname><given-names>C.-Y.</given-names></name><name><surname>Fu</surname><given-names>X.-Q.</given-names></name><name><surname>Guo</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Tse</surname><given-names>A.K.-W.</given-names></name><etal/></person-group><article-title>Inhibition of the stat3 signaling pathway contributes to apigenin-mediated anti-metastatic effect in melanoma</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>21731</fpage><pub-id pub-id-type="doi">10.1038/srep21731</pub-id><?supplied-pmid 26911838?><pub-id pub-id-type="pmid">26911838</pub-id></element-citation></ref><ref id="B45-ijms-20-04291"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Y.C.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Gao</surname><given-names>F.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>Z.B.</given-names></name><name><surname>Liu</surname><given-names>J.X.</given-names></name><name><surname>Jin</surname><given-names>L.Y.</given-names></name></person-group><article-title>Epigallocatechin gallate inhibits the growth of human lung cancer by directly targeting the egfr signaling pathway</article-title><source>Oncol. Rep.</source><year>2014</year><volume>31</volume><fpage>1343</fpage><lpage>1349</lpage><pub-id pub-id-type="doi">10.3892/or.2013.2933</pub-id><?supplied-pmid 24366444?><pub-id pub-id-type="pmid">24366444</pub-id></element-citation></ref><ref id="B46-ijms-20-04291"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>S.</given-names></name></person-group><article-title>Fisetin inhibits the growth and migration in the a549 human lung cancer cell line via the erk1/2 pathway</article-title><source>Exp. Ther. Med.</source><year>2018</year><volume>15</volume><fpage>2667</fpage><lpage>2673</lpage><pub-id pub-id-type="doi">10.3892/etm.2017.5666</pub-id><?supplied-pmid 29467859?><pub-id pub-id-type="pmid">29467859</pub-id></element-citation></ref><ref id="B47-ijms-20-04291"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name></person-group><article-title>New development of inhibitors targeting the pi3k/akt/mtor pathway in personalized treatment of non-small-cell lung cancer</article-title><source>Anti-Cancer Drugs</source><year>2015</year><volume>26</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1097/CAD.0000000000000172</pub-id><?supplied-pmid 25304988?><pub-id pub-id-type="pmid">25304988</pub-id></element-citation></ref><ref id="B48-ijms-20-04291"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>H.L.</given-names></name><name><surname>Chang</surname><given-names>Y.M.</given-names></name><name><surname>Lai</surname><given-names>S.C.</given-names></name><name><surname>Chen</surname><given-names>K.M.</given-names></name><name><surname>Wang</surname><given-names>K.C.</given-names></name><name><surname>Chiu</surname><given-names>T.T.</given-names></name><name><surname>Chang</surname><given-names>F.H.</given-names></name><name><surname>Hsu</surname><given-names>L.S.</given-names></name></person-group><article-title>Naringenin inhibits migration of lung cancer cells via the inhibition of matrix metalloproteinases-2 and -9</article-title><source>Exp. Ther. Med.</source><year>2017</year><volume>13</volume><fpage>739</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.3892/etm.2016.3994</pub-id><pub-id pub-id-type="pmid">28352360</pub-id></element-citation></ref><ref id="B49-ijms-20-04291"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Miao</surname><given-names>H.</given-names></name><name><surname>Zhu</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Huang</surname><given-names>H.</given-names></name></person-group><article-title>Daidzein induces apoptosis of non-small cell lung cancer cells by restoring STK 4/YAP 1 signaling</article-title><source>Int. J. Clin. Exp. Med.</source><year>2017</year><volume>10</volume><fpage>15205</fpage><lpage>15212</lpage></element-citation></ref><ref id="B50-ijms-20-04291"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cincin</surname><given-names>Z.B.</given-names></name><name><surname>Unlu</surname><given-names>M.</given-names></name><name><surname>Kiran</surname><given-names>B.</given-names></name><name><surname>Bireller</surname><given-names>E.S.</given-names></name><name><surname>Baran</surname><given-names>Y.</given-names></name><name><surname>Cakmakoglu</surname><given-names>B.</given-names></name></person-group><article-title>Molecular mechanisms of quercitrin-induced apoptosis in non-small cell lung cancer</article-title><source>Arch. Med. Res.</source><year>2014</year><volume>45</volume><fpage>445</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1016/j.arcmed.2014.08.002</pub-id><pub-id pub-id-type="pmid">25193878</pub-id></element-citation></ref><ref id="B51-ijms-20-04291"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irimie</surname><given-names>A.I.</given-names></name><name><surname>Braicu</surname><given-names>C.</given-names></name><name><surname>Pileczki</surname><given-names>V.</given-names></name><name><surname>Petrushev</surname><given-names>B.</given-names></name><name><surname>Soritau</surname><given-names>O.</given-names></name><name><surname>Campian</surname><given-names>R.S.</given-names></name><name><surname>Berindan-Neagoe</surname><given-names>I.</given-names></name></person-group><article-title>Knocking down of p53 triggers apoptosis and autophagy, concomitantly with inhibition of migration on ssc-4 oral squamous carcinoma cells</article-title><source>Mol. Cell. Biochem.</source><year>2016</year><volume>419</volume><fpage>75</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1007/s11010-016-2751-9</pub-id><?supplied-pmid 27370646?><pub-id pub-id-type="pmid">27370646</pub-id></element-citation></ref><ref id="B52-ijms-20-04291"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irimie</surname><given-names>A.I.</given-names></name><name><surname>Braicu</surname><given-names>C.</given-names></name><name><surname>Zanoaga</surname><given-names>O.</given-names></name><name><surname>Pileczki</surname><given-names>V.</given-names></name><name><surname>Gherman</surname><given-names>C.</given-names></name><name><surname>Berindan-Neagoe</surname><given-names>I.</given-names></name><name><surname>Campian</surname><given-names>R.S.</given-names></name></person-group><article-title>Epigallocatechin-3-gallate suppresses cell proliferation and promotes apoptosis and autophagy in oral cancer ssc-4 cells</article-title><source>Oncotargets Ther.</source><year>2015</year><volume>8</volume><fpage>461</fpage><lpage>470</lpage></element-citation></ref><ref id="B53-ijms-20-04291"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merkel</surname><given-names>O.</given-names></name><name><surname>Taylor</surname><given-names>N.</given-names></name><name><surname>Prutsch</surname><given-names>N.</given-names></name><name><surname>Staber</surname><given-names>P.B.</given-names></name><name><surname>Moriggl</surname><given-names>R.</given-names></name><name><surname>Turner</surname><given-names>S.D.</given-names></name><name><surname>Kenner</surname><given-names>L.</given-names></name></person-group><article-title>When the guardian sleeps: Reactivation of the p53 pathway in cancer</article-title><source>Mutat. Res.</source><year>2017</year><volume>773</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.mrrev.2017.02.003</pub-id><?supplied-pmid 28927521?><pub-id pub-id-type="pmid">28927521</pub-id></element-citation></ref><ref id="B54-ijms-20-04291"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vucic</surname><given-names>D.</given-names></name><name><surname>Dixit</surname><given-names>V.M.</given-names></name><name><surname>Wertz</surname><given-names>I.E.</given-names></name></person-group><article-title>Ubiquitylation in apoptosis: A post-translational modification at the edge of life and death</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2011</year><volume>12</volume><fpage>439</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1038/nrm3143</pub-id><?supplied-pmid 21697901?><pub-id pub-id-type="pmid">21697901</pub-id></element-citation></ref><ref id="B55-ijms-20-04291"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>R.</given-names></name><name><surname>Ji</surname><given-names>P.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>Qiao</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Deng</surname><given-names>T.</given-names></name><name><surname>Ba</surname><given-names>Y.</given-names></name></person-group><article-title>Apigenin enhances the cisplatin cytotoxic effect through p53-modulated apoptosis</article-title><source>Oncol. Lett.</source><year>2017</year><volume>13</volume><fpage>1024</fpage><lpage>1030</lpage><pub-id pub-id-type="doi">10.3892/ol.2016.5495</pub-id><pub-id pub-id-type="pmid">28356995</pub-id></element-citation></ref><ref id="B56-ijms-20-04291"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>K.-I.</given-names></name><name><surname>Park</surname><given-names>H.-S.</given-names></name><name><surname>Kim</surname><given-names>M.-K.</given-names></name><name><surname>Hong</surname><given-names>G.-E.</given-names></name><name><surname>Nagappan</surname><given-names>A.</given-names></name><name><surname>Lee</surname><given-names>H.-J.</given-names></name><name><surname>Yumnam</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>W.-S.</given-names></name><name><surname>Won</surname><given-names>C.-K.</given-names></name><name><surname>Shin</surname><given-names>S.-C.</given-names></name><etal/></person-group><article-title>Flavonoids identified from korean citrus aurantium l. Inhibit non-small cell lung cancer growth in vivo and in vitro</article-title><source>J. Funct. Foods</source><year>2014</year><volume>7</volume><fpage>287</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1016/j.jff.2014.01.032</pub-id></element-citation></ref><ref id="B57-ijms-20-04291"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Zha</surname><given-names>D.</given-names></name><name><surname>Cai</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>Q.</given-names></name><name><surname>Zhuang</surname><given-names>H.</given-names></name><name><surname>Hua</surname><given-names>Z.C.</given-names></name></person-group><article-title>Apigenin potentiates trail therapy of non-small cell lung cancer via upregulating dr4/dr5 expression in a p53-dependent manner</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>35468</fpage><pub-id pub-id-type="doi">10.1038/srep35468</pub-id><pub-id pub-id-type="pmid">27752089</pub-id></element-citation></ref><ref id="B58-ijms-20-04291"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuo</surname><given-names>P.C.</given-names></name><name><surname>Liu</surname><given-names>H.F.</given-names></name><name><surname>Chao</surname><given-names>J.I.</given-names></name></person-group><article-title>Survivin and p53 modulate quercetin-induced cell growth inhibition and apoptosis in human lung carcinoma cells</article-title><source>J. Biol. Chem.</source><year>2004</year><volume>279</volume><fpage>55875</fpage><lpage>55885</lpage><pub-id pub-id-type="doi">10.1074/jbc.M407985200</pub-id><pub-id pub-id-type="pmid">15456784</pub-id></element-citation></ref><ref id="B59-ijms-20-04291"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsui</surname><given-names>K.C.</given-names></name><name><surname>Chiang</surname><given-names>T.H.</given-names></name><name><surname>Wang</surname><given-names>J.S.</given-names></name><name><surname>Lin</surname><given-names>L.J.</given-names></name><name><surname>Chao</surname><given-names>W.C.</given-names></name><name><surname>Chen</surname><given-names>B.H.</given-names></name><name><surname>Lu</surname><given-names>J.F.</given-names></name></person-group><article-title>Flavonoids from gynostemma pentaphyllum exhibit differential induction of cell cycle arrest in h460 and a549 cancer cells</article-title><source>Molecules</source><year>2014</year><volume>19</volume><fpage>17663</fpage><lpage>17681</lpage><pub-id pub-id-type="doi">10.3390/molecules191117663</pub-id><pub-id pub-id-type="pmid">25365293</pub-id></element-citation></ref><ref id="B60-ijms-20-04291"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elango</surname><given-names>R.</given-names></name><name><surname>Athinarayanan</surname><given-names>J.</given-names></name><name><surname>Subbarayan</surname><given-names>V.P.</given-names></name><name><surname>Lei</surname><given-names>D.K.Y.</given-names></name><name><surname>Alshatwi</surname><given-names>A.A.</given-names></name></person-group><article-title>Hesperetin induces an apoptosis-triggered extrinsic pathway and a p53- independent pathway in human lung cancer h522 cells</article-title><source>J. Asian Nat. Prod. Res.</source><year>2018</year><volume>20</volume><fpage>559</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1080/10286020.2017.1327949</pub-id><pub-id pub-id-type="pmid">28537448</pub-id></element-citation></ref><ref id="B61-ijms-20-04291"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>X.</given-names></name><name><surname>Ye</surname><given-names>T.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Lu</surname><given-names>W.</given-names></name><name><surname>Lu</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Cao</surname><given-names>P.</given-names></name></person-group><article-title>Luteolin induced g2 phase cell cycle arrest and apoptosis on non-small cell lung cancer cells</article-title><source>Toxicol. Vitr. Int. J. Publ. Assoc. Bibra</source><year>2011</year><volume>25</volume><fpage>1385</fpage><lpage>1391</lpage><pub-id pub-id-type="doi">10.1016/j.tiv.2011.05.009</pub-id><?supplied-pmid 21601631?><pub-id pub-id-type="pmid">21601631</pub-id></element-citation></ref><ref id="B62-ijms-20-04291"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Z.Q.</given-names></name><name><surname>Li</surname><given-names>M.H.</given-names></name><name><surname>Qin</surname><given-names>Y.M.</given-names></name><name><surname>Jiang</surname><given-names>H.Y.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>M.H.</given-names></name></person-group><article-title>Luteolin inhibits tumorigenesis and induces apoptosis of non-small cell lung cancer cells via regulation of microrna-34a-5p</article-title><source>Int. J. Mol. Sci.</source><year>2018</year><volume>19</volume><elocation-id>447</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19020447</pub-id></element-citation></ref><ref id="B63-ijms-20-04291"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>L.</given-names></name><name><surname>Peng</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>K.</given-names></name><name><surname>Zhao</surname><given-names>R.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Yu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Han</surname><given-names>Z.</given-names></name></person-group><article-title>Luteolin exerts an anticancer effect on nci-h460 human non-small cell lung cancer cells through the induction of sirt1-mediated apoptosis</article-title><source>Mol. Med. Rep.</source><year>2015</year><volume>12</volume><fpage>4196</fpage><lpage>4202</lpage><pub-id pub-id-type="doi">10.3892/mmr.2015.3956</pub-id><?supplied-pmid 26096576?><pub-id pub-id-type="pmid">26096576</pub-id></element-citation></ref><ref id="B64-ijms-20-04291"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>C.Y.</given-names></name><name><surname>Park</surname><given-names>C.</given-names></name><name><surname>Hwang</surname><given-names>H.J.</given-names></name><name><surname>Kim</surname><given-names>G.Y.</given-names></name><name><surname>Choi</surname><given-names>B.T.</given-names></name><name><surname>Kim</surname><given-names>W.J.</given-names></name><name><surname>Choi</surname><given-names>Y.H.</given-names></name></person-group><article-title>Naringenin up-regulates the expression of death receptor 5 and enhances trail-induced apoptosis in human lung cancer a549 cells</article-title><source>Mol. Nutr. Food Res.</source><year>2011</year><volume>55</volume><fpage>300</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1002/mnfr.201000024</pub-id><?supplied-pmid 20669244?><pub-id pub-id-type="pmid">20669244</pub-id></element-citation></ref><ref id="B65-ijms-20-04291"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>J.J.</given-names></name><name><surname>Qiao</surname><given-names>K.S.</given-names></name><name><surname>Sun</surname><given-names>P.</given-names></name><name><surname>Chen</surname><given-names>P.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name></person-group><article-title>Study of egcg induced apoptosis in lung cancer cells by inhibiting pi3k/akt signaling pathway</article-title><source>Eur. Rev. Med Pharmacol. Sci.</source><year>2018</year><volume>22</volume><fpage>4557</fpage><lpage>4563</lpage><?supplied-pmid 30058690?><pub-id pub-id-type="pmid">30058690</pub-id></element-citation></ref><ref id="B66-ijms-20-04291"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Dong</surname><given-names>Y.</given-names></name></person-group><article-title>Effect of genistein on apoptosis of lung adenocarcinoma a549 cells and expression of apoptosis factors</article-title><source>J. B.U. Off. J. Balk. Union Oncol.</source><year>2018</year><volume>23</volume><fpage>641</fpage><lpage>646</lpage></element-citation></ref><ref id="B67-ijms-20-04291"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravishankar</surname><given-names>D.</given-names></name><name><surname>Rajora</surname><given-names>A.K.</given-names></name><name><surname>Greco</surname><given-names>F.</given-names></name><name><surname>Osborn</surname><given-names>H.M.</given-names></name></person-group><article-title>Flavonoids as prospective compounds for anti-cancer therapy</article-title><source>Int. J. Biochem. Cell Biol.</source><year>2013</year><volume>45</volume><fpage>2821</fpage><lpage>2831</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2013.10.004</pub-id><?supplied-pmid 24128857?><pub-id pub-id-type="pmid">24128857</pub-id></element-citation></ref><ref id="B68-ijms-20-04291"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Gao</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Pan</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name></person-group><article-title>Insights on structural characteristics and ligand binding mechanisms of cdk2</article-title><source>Int. J. Mol. Sci.</source><year>2015</year><volume>16</volume><fpage>9314</fpage><lpage>9340</lpage><pub-id pub-id-type="doi">10.3390/ijms16059314</pub-id><?supplied-pmid 25918937?><pub-id pub-id-type="pmid">25918937</pub-id></element-citation></ref><ref id="B69-ijms-20-04291"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramteke</surname><given-names>P.</given-names></name><name><surname>Yadav</surname><given-names>U.C.S.</given-names></name></person-group><article-title>Hesperetin, a Citrus bioflavonoid, prevents IL-1&#x003b2;-induced inflammation and cell proliferation in lung epithelial A549 cells</article-title><source>Indian J. Exp. Biol.</source><year>2019</year><volume>57</volume><fpage>7</fpage><lpage>14</lpage><comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://nopr.niscair.res.in/handle/123456789/45568">http://nopr.niscair.res.in/handle/123456789/45568</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-06-24">(accessed on 24 June 2019)</date-in-citation></element-citation></ref><ref id="B70-ijms-20-04291"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>M.H.</given-names></name><name><surname>Jeong</surname><given-names>Y.J.</given-names></name><name><surname>Cho</surname><given-names>H.J.</given-names></name><name><surname>Hoe</surname><given-names>H.S.</given-names></name><name><surname>Park</surname><given-names>K.K.</given-names></name><name><surname>Park</surname><given-names>Y.Y.</given-names></name><name><surname>Choi</surname><given-names>Y.H.</given-names></name><name><surname>Kim</surname><given-names>C.H.</given-names></name><name><surname>Chang</surname><given-names>H.W.</given-names></name><name><surname>Park</surname><given-names>Y.J.</given-names></name><etal/></person-group><article-title>Delphinidin inhibits angiogenesis through the suppression of hif-1alpha and vegf expression in a549 lung cancer cells</article-title><source>Oncol. Rep.</source><year>2017</year><volume>37</volume><fpage>777</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.3892/or.2016.5296</pub-id><pub-id pub-id-type="pmid">27959445</pub-id></element-citation></ref><ref id="B71-ijms-20-04291"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pal</surname><given-names>H.C.</given-names></name><name><surname>Sharma</surname><given-names>S.</given-names></name><name><surname>Strickland</surname><given-names>L.R.</given-names></name><name><surname>Agarwal</surname><given-names>J.</given-names></name><name><surname>Athar</surname><given-names>M.</given-names></name><name><surname>Elmets</surname><given-names>C.A.</given-names></name><name><surname>Afaq</surname><given-names>F.</given-names></name></person-group><article-title>Delphinidin reduces cell proliferation and induces apoptosis of non-small-cell lung cancer cells by targeting egfr/vegfr2 signaling pathways</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e77270</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0077270</pub-id><?supplied-pmid 24124611?><pub-id pub-id-type="pmid">24124611</pub-id></element-citation></ref><ref id="B72-ijms-20-04291"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>G.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name></person-group><article-title>Baicalein suppresses non small cell lung cancer cell proliferation, invasion and notch signaling pathway</article-title><source>Cancer Biomark.</source><year>2018</year><volume>22</volume><fpage>13</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.3233/CBM-170673</pub-id><?supplied-pmid 29614624?><pub-id pub-id-type="pmid">29614624</pub-id></element-citation></ref><ref id="B73-ijms-20-04291"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>H.</given-names></name><name><surname>So</surname><given-names>Y.</given-names></name><name><surname>Jeon</surname><given-names>H.</given-names></name><name><surname>Jeong</surname><given-names>M.H.</given-names></name><name><surname>Choi</surname><given-names>H.K.</given-names></name><name><surname>Ryu</surname><given-names>S.H.</given-names></name><name><surname>Lee</surname><given-names>S.W.</given-names></name><name><surname>Yoon</surname><given-names>H.G.</given-names></name><name><surname>Choi</surname><given-names>K.C.</given-names></name></person-group><article-title>Tgf-beta1-induced epithelial-mesenchymal transition and acetylation of smad2 and smad3 are negatively regulated by egcg in human a549 lung cancer cells</article-title><source>Cancer Lett.</source><year>2013</year><volume>335</volume><fpage>205</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2013.02.018</pub-id><?supplied-pmid 23419524?><pub-id pub-id-type="pmid">23419524</pub-id></element-citation></ref><ref id="B74-ijms-20-04291"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irimie</surname><given-names>A.I.</given-names></name><name><surname>Braicu</surname><given-names>C.</given-names></name><name><surname>Sonea</surname><given-names>L.</given-names></name><name><surname>Zimta</surname><given-names>A.A.</given-names></name><name><surname>Cojocneanu-Petric</surname><given-names>R.</given-names></name><name><surname>Tonchev</surname><given-names>K.</given-names></name><name><surname>Mehterov</surname><given-names>N.</given-names></name><name><surname>Diudea</surname><given-names>D.</given-names></name><name><surname>Buduru</surname><given-names>S.</given-names></name><name><surname>Berindan-Neagoe</surname><given-names>I.</given-names></name></person-group><article-title>A looking-glass of non-coding rnas in oral cancer</article-title><source>Int. J. Mol. Sci.</source><year>2017</year><volume>18</volume><elocation-id>2620</elocation-id><pub-id pub-id-type="doi">10.3390/ijms18122620</pub-id><?supplied-pmid 29206174?><pub-id pub-id-type="pmid">29206174</pub-id></element-citation></ref><ref id="B75-ijms-20-04291"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braicu</surname><given-names>C.</given-names></name><name><surname>Zimta</surname><given-names>A.A.</given-names></name><name><surname>Gulei</surname><given-names>D.</given-names></name><name><surname>Olariu</surname><given-names>A.</given-names></name><name><surname>Berindan-Neagoe</surname><given-names>I.</given-names></name></person-group><article-title>Comprehensive analysis of circular rnas in pathological states: Biogenesis, cellular regulation, and therapeutic relevance</article-title><source>Cell. Mol. Life Sci.</source><year>2019</year><pub-id pub-id-type="doi">10.1007/s00018-019-03016-5</pub-id><?supplied-pmid 30805658?><pub-id pub-id-type="pmid">30805658</pub-id></element-citation></ref><ref id="B76-ijms-20-04291"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braicu</surname><given-names>C.</given-names></name><name><surname>Catana</surname><given-names>C.</given-names></name><name><surname>Calin</surname><given-names>G.A.</given-names></name><name><surname>Berindan-Neagoe</surname><given-names>I.</given-names></name></person-group><article-title>Ncrna combined therapy as future treatment option for cancer</article-title><source>Curr. Pharm. Des.</source><year>2014</year><volume>20</volume><fpage>6565</fpage><lpage>6574</lpage><pub-id pub-id-type="doi">10.2174/1381612820666140826153529</pub-id><?supplied-pmid 25341933?><pub-id pub-id-type="pmid">25341933</pub-id></element-citation></ref><ref id="B77-ijms-20-04291"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berindan-Neagoe</surname><given-names>I.</given-names></name><name><surname>Calin</surname><given-names>G.A.</given-names></name></person-group><article-title>Molecular pathways: Micrornas, cancer cells, and microenvironment</article-title><source>Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.</source><year>2014</year><volume>20</volume><fpage>6247</fpage><lpage>6253</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-2500</pub-id></element-citation></ref><ref id="B78-ijms-20-04291"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braicu</surname><given-names>C.</given-names></name><name><surname>Pileczki</surname><given-names>V.</given-names></name><name><surname>Irimie</surname><given-names>A.</given-names></name><name><surname>Berindan-Neagoe</surname><given-names>I.</given-names></name></person-group><article-title>P53sirna therapy reduces cell proliferation, migration and induces apoptosis in triple negative breast cancer cells</article-title><source>Mol. Cell. Biochem.</source><year>2013</year><volume>381</volume><fpage>61</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1007/s11010-013-1688-5</pub-id><pub-id pub-id-type="pmid">23881244</pub-id></element-citation></ref><ref id="B79-ijms-20-04291"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seles</surname><given-names>M.</given-names></name><name><surname>Hutterer</surname><given-names>G.C.</given-names></name><name><surname>Kiesslich</surname><given-names>T.</given-names></name><name><surname>Pummer</surname><given-names>K.</given-names></name><name><surname>Berindan-Neagoe</surname><given-names>I.</given-names></name><name><surname>Perakis</surname><given-names>S.</given-names></name><name><surname>Schwarzenbacher</surname><given-names>D.</given-names></name><name><surname>Stotz</surname><given-names>M.</given-names></name><name><surname>Gerger</surname><given-names>A.</given-names></name><name><surname>Pichler</surname><given-names>M.</given-names></name></person-group><article-title>Current insights into long non-coding rnas in renal cell carcinoma</article-title><source>Int. J. Mol. Sci.</source><year>2016</year><volume>17</volume><elocation-id>573</elocation-id><pub-id pub-id-type="doi">10.3390/ijms17040573</pub-id><pub-id pub-id-type="pmid">27092491</pub-id></element-citation></ref><ref id="B80-ijms-20-04291"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De la Parra</surname><given-names>C.</given-names></name><name><surname>Castillo-Pichardo</surname><given-names>L.</given-names></name><name><surname>Cruz-Collazo</surname><given-names>A.</given-names></name><name><surname>Cubano</surname><given-names>L.</given-names></name><name><surname>Redis</surname><given-names>R.</given-names></name><name><surname>Calin</surname><given-names>G.A.</given-names></name><name><surname>Dharmawardhane</surname><given-names>S.</given-names></name></person-group><article-title>Soy isoflavone genistein-mediated downregulation of mir-155 contributes to the anticancer effects of genistein</article-title><source>Nutr. Cancer</source><year>2016</year><volume>68</volume><fpage>154</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1080/01635581.2016.1115104</pub-id><pub-id pub-id-type="pmid">26771440</pub-id></element-citation></ref><ref id="B81-ijms-20-04291"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhardwaj</surname><given-names>V.</given-names></name><name><surname>Mandal</surname><given-names>A.K.A.</given-names></name></person-group><article-title>Next-generation sequencing reveals the role of epigallocatechin-3-gallate in regulating putative novel and known micrornas which target the mapk pathway in non-small-cell lung cancer a549 cells</article-title><source>Molecules</source><year>2019</year><volume>24</volume><elocation-id>368</elocation-id><pub-id pub-id-type="doi">10.3390/molecules24020368</pub-id><?supplied-pmid 30669618?><pub-id pub-id-type="pmid">30669618</pub-id></element-citation></ref><ref id="B82-ijms-20-04291"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>G.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Shi</surname><given-names>J.</given-names></name></person-group><article-title>Mir-98 inhibits cell proliferation and invasion of non-small cell carcinoma lung cancer by targeting pak1</article-title><source>Int. J. Clin. Exp. Med.</source><year>2015</year><volume>8</volume><fpage>20135</fpage><lpage>20145</lpage><?supplied-pmid 26884926?><pub-id pub-id-type="pmid">26884926</pub-id></element-citation></ref><ref id="B83-ijms-20-04291"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>D.H.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Feng</surname><given-names>Q.</given-names></name></person-group><article-title>Egcg enhances the efficacy of cisplatin by downregulating hsa-mir-98-5p in nsclc a549 cells</article-title><source>Nutr. Cancer</source><year>2014</year><volume>66</volume><fpage>636</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1080/01635581.2014.894101</pub-id><?supplied-pmid 24712372?><pub-id pub-id-type="pmid">24712372</pub-id></element-citation></ref><ref id="B84-ijms-20-04291"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Bian</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>C.S.</given-names></name></person-group><article-title>Green tea polyphenol egcg suppresses lung cancer cell growth through upregulating mir-210 expression caused by stabilizing hif-1alpha</article-title><source>Carcinogenesis</source><year>2011</year><volume>32</volume><fpage>1881</fpage><lpage>1889</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgr218</pub-id><?supplied-pmid 21965273?><pub-id pub-id-type="pmid">21965273</pub-id></element-citation></ref><ref id="B85-ijms-20-04291"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Zang</surname><given-names>A.</given-names></name><name><surname>Jia</surname><given-names>Y.</given-names></name><name><surname>Shang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Ge</surname><given-names>K.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Fan</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name></person-group><article-title>Genistein inhibits a549 human lung cancer cell proliferation via mir-27a and met signaling</article-title><source>Oncol. Lett.</source><year>2016</year><volume>12</volume><fpage>2189</fpage><lpage>2193</lpage><pub-id pub-id-type="doi">10.3892/ol.2016.4817</pub-id><?supplied-pmid 27602162?><pub-id pub-id-type="pmid">27602162</pub-id></element-citation></ref><ref id="B86-ijms-20-04291"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navarro</surname><given-names>A.</given-names></name><name><surname>Diaz</surname><given-names>T.</given-names></name><name><surname>Gallardo</surname><given-names>E.</given-names></name><name><surname>Vinolas</surname><given-names>N.</given-names></name><name><surname>Marrades</surname><given-names>R.M.</given-names></name><name><surname>Gel</surname><given-names>B.</given-names></name><name><surname>Campayo</surname><given-names>M.</given-names></name><name><surname>Quera</surname><given-names>A.</given-names></name><name><surname>Bandres</surname><given-names>E.</given-names></name><name><surname>Garcia-Foncillas</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Prognostic implications of mir-16 expression levels in resected non-small-cell lung cancer</article-title><source>J. Surg. Oncol.</source><year>2011</year><volume>103</volume><fpage>411</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1002/jso.21847</pub-id><pub-id pub-id-type="pmid">21400525</pub-id></element-citation></ref><ref id="B87-ijms-20-04291"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andriani</surname><given-names>F.</given-names></name><name><surname>Majorini</surname><given-names>M.T.</given-names></name><name><surname>Mano</surname><given-names>M.</given-names></name><name><surname>Landoni</surname><given-names>E.</given-names></name><name><surname>Miceli</surname><given-names>R.</given-names></name><name><surname>Facchinetti</surname><given-names>F.</given-names></name><name><surname>Mensah</surname><given-names>M.</given-names></name><name><surname>Fontanella</surname><given-names>E.</given-names></name><name><surname>Dugo</surname><given-names>M.</given-names></name><name><surname>Giacca</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Mir-16 regulates the pro-tumorigenic potential of lung fibroblasts through the inhibition of hgf production in an fgfr-1- and mek1-dependent manner</article-title><source>J. Hematol. Oncol.</source><year>2018</year><volume>11</volume><fpage>45</fpage><pub-id pub-id-type="doi">10.1186/s13045-018-0594-4</pub-id><pub-id pub-id-type="pmid">29558956</pub-id></element-citation></ref><ref id="B88-ijms-20-04291"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonoki</surname><given-names>H.</given-names></name><name><surname>Sato</surname><given-names>T.</given-names></name><name><surname>Endo</surname><given-names>S.</given-names></name><name><surname>Matsunaga</surname><given-names>T.</given-names></name><name><surname>Yamaguchi</surname><given-names>M.</given-names></name><name><surname>Yamazaki</surname><given-names>Y.</given-names></name><name><surname>Sugatani</surname><given-names>J.</given-names></name><name><surname>Ikari</surname><given-names>A.</given-names></name></person-group><article-title>Quercetin decreases claudin-2 expression mediated by up-regulation of microrna mir-16 in lung adenocarcinoma a549 cells</article-title><source>Nutrients</source><year>2015</year><volume>7</volume><fpage>4578</fpage><lpage>4592</lpage><pub-id pub-id-type="doi">10.3390/nu7064578</pub-id><pub-id pub-id-type="pmid">26061016</pub-id></element-citation></ref><ref id="B89-ijms-20-04291"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>S.</given-names></name><name><surname>Risolino</surname><given-names>M.</given-names></name><name><surname>Mandia</surname><given-names>N.</given-names></name><name><surname>Talotta</surname><given-names>F.</given-names></name><name><surname>Soini</surname><given-names>Y.</given-names></name><name><surname>Incoronato</surname><given-names>M.</given-names></name><name><surname>Condorelli</surname><given-names>G.</given-names></name><name><surname>Banfi</surname><given-names>S.</given-names></name><name><surname>Verde</surname><given-names>P.</given-names></name></person-group><article-title>Mir-340 inhibits tumor cell proliferation and induces apoptosis by targeting multiple negative regulators of p27 in non-small cell lung cancer</article-title><source>Oncogene</source><year>2015</year><volume>34</volume><fpage>3240</fpage><lpage>3250</lpage><pub-id pub-id-type="doi">10.1038/onc.2014.267</pub-id><pub-id pub-id-type="pmid">25151966</pub-id></element-citation></ref><ref id="B90-ijms-20-04291"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brito</surname><given-names>A.F.</given-names></name><name><surname>Ribeiro</surname><given-names>M.</given-names></name><name><surname>Abrantes</surname><given-names>A.M.</given-names></name><name><surname>Pires</surname><given-names>A.S.</given-names></name><name><surname>Teixo</surname><given-names>R.J.</given-names></name><name><surname>Tralhao</surname><given-names>J.G.</given-names></name><name><surname>Botelho</surname><given-names>M.F.</given-names></name></person-group><article-title>Quercetin in cancer treatment, alone or in combination with conventional therapeutics?</article-title><source>Curr. Med. Chem.</source><year>2015</year><volume>22</volume><fpage>3025</fpage><lpage>3039</lpage><pub-id pub-id-type="doi">10.2174/0929867322666150812145435</pub-id><pub-id pub-id-type="pmid">26264923</pub-id></element-citation></ref><ref id="B91-ijms-20-04291"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrushev</surname><given-names>B.</given-names></name><name><surname>Tomuleasa</surname><given-names>C.</given-names></name><name><surname>Soritau</surname><given-names>O.</given-names></name><name><surname>Aldea</surname><given-names>M.</given-names></name><name><surname>Pop</surname><given-names>T.</given-names></name><name><surname>Susman</surname><given-names>S.</given-names></name><name><surname>Kacso</surname><given-names>G.</given-names></name><name><surname>Berindan</surname><given-names>I.</given-names></name><name><surname>Irimie</surname><given-names>A.</given-names></name><name><surname>Cristea</surname><given-names>V.</given-names></name></person-group><article-title>Metformin plus piaf combination chemotherapy for hepatocellular carcinoma</article-title><source>Exp. Oncol.</source><year>2012</year><volume>34</volume><fpage>17</fpage><lpage>24</lpage><?supplied-pmid 22453143?><pub-id pub-id-type="pmid">22453143</pub-id></element-citation></ref><ref id="B92-ijms-20-04291"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grozav</surname><given-names>A.</given-names></name><name><surname>Balacescu</surname><given-names>O.</given-names></name><name><surname>Balacescu</surname><given-names>L.</given-names></name><name><surname>Cheminel</surname><given-names>T.</given-names></name><name><surname>Berindan-Neagoe</surname><given-names>I.</given-names></name><name><surname>Therrien</surname><given-names>B.</given-names></name></person-group><article-title>Synthesis, anticancer activity, and genome profiling of thiazolo arene ruthenium complexes</article-title><source>J. Med. Chem.</source><year>2015</year><volume>58</volume><fpage>8475</fpage><lpage>8490</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b00855</pub-id><pub-id pub-id-type="pmid">26488797</pub-id></element-citation></ref><ref id="B93-ijms-20-04291"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>P.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Huang</surname><given-names>W.</given-names></name><name><surname>Feng</surname><given-names>Q.</given-names></name></person-group><article-title>Neat1 upregulates egcg-induced ctr1 to enhance cisplatin sensitivity in lung cancer cells</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>43337</fpage><lpage>43351</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.9712</pub-id><?supplied-pmid 27270317?><pub-id pub-id-type="pmid">27270317</pub-id></element-citation></ref><ref id="B94-ijms-20-04291"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>C.</given-names></name><name><surname>Jiao</surname><given-names>Y.</given-names></name><name><surname>Xue</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Xing</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>G.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Zhu</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Metformin sensitizes non-small cell lung cancer cells to an epigallocatechin-3-gallate (egcg) treatment by suppressing the nrf2/ho-1 signaling pathway</article-title><source>Int. J. Biol. Sci.</source><year>2017</year><volume>13</volume><fpage>1560</fpage><lpage>1569</lpage><pub-id pub-id-type="doi">10.7150/ijbs.18830</pub-id><?supplied-pmid 29230104?><pub-id pub-id-type="pmid">29230104</pub-id></element-citation></ref><ref id="B95-ijms-20-04291"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S.H.</given-names></name><name><surname>Lee</surname><given-names>E.J.</given-names></name><name><surname>Min</surname><given-names>K.H.</given-names></name><name><surname>Hur</surname><given-names>G.Y.</given-names></name><name><surname>Lee</surname><given-names>S.H.</given-names></name><name><surname>Lee</surname><given-names>S.Y.</given-names></name><name><surname>Kim</surname><given-names>J.H.</given-names></name><name><surname>Shin</surname><given-names>C.</given-names></name><name><surname>Shim</surname><given-names>J.J.</given-names></name><name><surname>In</surname><given-names>K.H.</given-names></name><etal/></person-group><article-title>Quercetin enhances chemosensitivity to gemcitabine in lung cancer cells by inhibiting heat shock protein 70 expression</article-title><source>Clin. Lung Cancer</source><year>2015</year><volume>16</volume><fpage>e235</fpage><lpage>e243</lpage><pub-id pub-id-type="doi">10.1016/j.cllc.2015.05.006</pub-id><?supplied-pmid 26050647?><pub-id pub-id-type="pmid">26050647</pub-id></element-citation></ref><ref id="B96-ijms-20-04291"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>Y.J.</given-names></name><name><surname>Hwang</surname><given-names>I.S.</given-names></name><name><surname>Lee</surname><given-names>Y.J.</given-names></name><name><surname>Lee</surname><given-names>C.H.</given-names></name><name><surname>Kim</surname><given-names>S.H.</given-names></name><name><surname>Nam</surname><given-names>H.S.</given-names></name><name><surname>Choi</surname><given-names>Y.J.</given-names></name><name><surname>Lee</surname><given-names>S.H.</given-names></name></person-group><article-title>Knockdown of bcl-xl enhances growth-inhibiting and apoptosis-inducing effects of resveratrol and clofarabine in malignant mesothelioma h-2452 cells</article-title><source>J. Korean Med. Sci.</source><year>2014</year><volume>29</volume><fpage>1464</fpage><lpage>1472</lpage><pub-id pub-id-type="doi">10.3346/jkms.2014.29.11.1464</pub-id><pub-id pub-id-type="pmid">25408576</pub-id></element-citation></ref><ref id="B97-ijms-20-04291"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nie</surname><given-names>P.</given-names></name><name><surname>Hu</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>T.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Hou</surname><given-names>B.</given-names></name><name><surname>Zou</surname><given-names>Z.</given-names></name></person-group><article-title>Synergistic induction of erlotinib-mediated apoptosis by resveratrol in human non-small-cell lung cancer cells by down-regulating survivin and up-regulating puma</article-title><source>Cell. Physiol. Biochem.</source><year>2015</year><volume>35</volume><fpage>2255</fpage><lpage>2271</lpage><pub-id pub-id-type="doi">10.1159/000374030</pub-id><pub-id pub-id-type="pmid">25895606</pub-id></element-citation></ref><ref id="B98-ijms-20-04291"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>R.Z.</given-names></name><name><surname>Jiang</surname><given-names>Z.B.</given-names></name><name><surname>Wei</surname><given-names>C.L.</given-names></name><name><surname>Luo</surname><given-names>L.X.</given-names></name><name><surname>Yao</surname><given-names>X.J.</given-names></name><name><surname>Li</surname><given-names>G.P.</given-names></name><name><surname>Leung</surname><given-names>E.L.</given-names></name></person-group><article-title>Honokiol inhibits proliferation, invasion and induces apoptosis through targeting lyn kinase in human lung adenocarcinoma cells</article-title><source>Front. Pharmacol.</source><year>2018</year><volume>9</volume><fpage>558</fpage><pub-id pub-id-type="doi">10.3389/fphar.2018.00558</pub-id><pub-id pub-id-type="pmid">29892225</pub-id></element-citation></ref><ref id="B99-ijms-20-04291"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klimaszewska-Wisniewska</surname><given-names>A.</given-names></name><name><surname>Halas-Wisniewska</surname><given-names>M.</given-names></name><name><surname>Tadrowski</surname><given-names>T.</given-names></name><name><surname>Gagat</surname><given-names>M.</given-names></name><name><surname>Grzanka</surname><given-names>D.</given-names></name><name><surname>Grzanka</surname><given-names>A.</given-names></name></person-group><article-title>Paclitaxel and the dietary flavonoid fisetin: A synergistic combination that induces mitotic catastrophe and autophagic cell death in a549 non-small cell lung cancer cells</article-title><source>Cancer Cell Int.</source><year>2016</year><volume>16</volume><fpage>10</fpage><pub-id pub-id-type="doi">10.1186/s12935-016-0288-3</pub-id><pub-id pub-id-type="pmid">26884726</pub-id></element-citation></ref><ref id="B100-ijms-20-04291"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>You</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>R.</given-names></name><name><surname>Park</surname><given-names>D.</given-names></name><name><surname>Xie</surname><given-names>M.</given-names></name><name><surname>Sica</surname><given-names>G.L.</given-names></name><name><surname>Cao</surname><given-names>Y.</given-names></name><name><surname>Xiao</surname><given-names>Z.Q.</given-names></name><name><surname>Deng</surname><given-names>X.</given-names></name></person-group><article-title>Disruption of stat3 by niclosamide reverses radioresistance of human lung cancer</article-title><source>Mol. Cancer Ther.</source><year>2014</year><volume>13</volume><fpage>606</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-13-0608</pub-id><pub-id pub-id-type="pmid">24362463</pub-id></element-citation></ref><ref id="B101-ijms-20-04291"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Jin</surname><given-names>F.</given-names></name><name><surname>Lian</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Lan</surname><given-names>B.</given-names></name><name><surname>He</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>G.D.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Sun</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Genistein promotes ionizing radiation-induced cell death by reducing cytoplasmic bcl-xl levels in non-small cell lung cancer</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>328</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-18755-3</pub-id><?supplied-pmid 29321496?><pub-id pub-id-type="pmid">29321496</pub-id></element-citation></ref><ref id="B102-ijms-20-04291"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>M.</given-names></name><name><surname>Qi</surname><given-names>B.</given-names></name><name><surname>Xiaoxiang</surname><given-names>W.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name></person-group><article-title>Baicalein increases cisplatin sensitivity of a549 lung adenocarcinoma cells via pi3k/akt/nf-kappab pathway</article-title><source>Biomed. Pharmacother.</source><year>2017</year><volume>90</volume><fpage>677</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2017.04.001</pub-id><?supplied-pmid 28415048?><pub-id pub-id-type="pmid">28415048</pub-id></element-citation></ref><ref id="B103-ijms-20-04291"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>Q.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Deng</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name></person-group><article-title>Diosmetin induces apoptosis and enhances the chemotherapeutic efficacy of paclitaxel in non-small cell lung cancer cells via nrf2 inhibition</article-title><source>Br. J. Pharmacol.</source><year>2019</year><pub-id pub-id-type="doi">10.1111/bph.14652</pub-id><?supplied-pmid 30825187?><pub-id pub-id-type="pmid">30825187</pub-id></element-citation></ref><ref id="B104-ijms-20-04291"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>H.S.</given-names></name><name><surname>Koo</surname><given-names>T.H.</given-names></name></person-group><article-title>Heavy metal concentrations in three shorebird species from okgu mudflat, gunsan, korea</article-title><source>Ecotoxicology</source><year>2009</year><volume>18</volume><fpage>61</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1007/s10646-008-0257-2</pub-id><?supplied-pmid 18763038?><pub-id pub-id-type="pmid">18763038</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="ijms-20-04291-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Chemical structure of the main flavonoids.</p></caption><graphic xlink:href="ijms-20-04291-g001"/></fig><fig id="ijms-20-04291-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Schematic representation of the mechanism of action of flavonoids as RTK inhibitors, by inhibiting key signal transduction pathways involved in lung cancer.</p></caption><graphic xlink:href="ijms-20-04291-g002"/></fig><fig id="ijms-20-04291-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>The modulation of cellular signaling pathways by flavonoids, targeting multiple cellular components altered in lung cancer protein kinases C (PKCs) via integrin as an important step in the regulation of cell proliferation and cellular adhesion. Further, RTK interacts with MAPK, NFkB PI3K/Akt and targets of STAT and anti-apoptotic proteins, emphasizing the complex compensatory alterations in lung cancer.</p></caption><graphic xlink:href="ijms-20-04291-g003"/></fig><table-wrap id="ijms-20-04291-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">ijms-20-04291-t001_Table 1</object-id><label>Table 1</label><caption><p>Anti-lung cancer mechanism modulated by flavonoids.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Class of Flavonois</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Representants</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Source</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Effect on Cells</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flavones</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Apigenin, luteolin and diosmetin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Parsley, celery leaf, pepper, broccoli</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-inflammatory, activation of apoptosis, anti-proliferation, anti-migration, and anti-invasion effects</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B21-ijms-20-04291" ref-type="bibr">21</xref>,<xref rid="B31-ijms-20-04291" ref-type="bibr">31</xref>,<xref rid="B32-ijms-20-04291" ref-type="bibr">32</xref>,<xref rid="B33-ijms-20-04291" ref-type="bibr">33</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flavonols</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">kaempherol, quercetin and myricetin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Brussel sprouts, apples, onion, leek and beans</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-inflammatory, antiproliferative effect, activation of apoptosis and autophagy cell adhesion, invasion and metastasis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B23-ijms-20-04291" ref-type="bibr">23</xref>,<xref rid="B24-ijms-20-04291" ref-type="bibr">24</xref>,<xref rid="B25-ijms-20-04291" ref-type="bibr">25</xref>,<xref rid="B34-ijms-20-04291" ref-type="bibr">34</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flavanons</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hesperitin, naringenin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Citrus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-inflammatory effects, Inhibition of cell proliferation, activation of apoptosis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B26-ijms-20-04291" ref-type="bibr">26</xref>,<xref rid="B35-ijms-20-04291" ref-type="bibr">35</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flavanols</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">catechin, epicatechin gallate, epigallocatechin, epigallocatechin gallate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">apples, pears, grapes, berries green tea and cocoa</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">suppressing proliferation, inducing apoptosis, inhibition of EMT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B36-ijms-20-04291" ref-type="bibr">36</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Isoflavons</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">daidzein, genistein, glycitein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Soy products</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inducing apoptosis, cell cycle arrest, targeting tyrosine kinase inhibitors</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-ijms-20-04291" ref-type="bibr">29</xref>,<xref rid="B37-ijms-20-04291" ref-type="bibr">37</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anthocyanidins</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">delphinidin, malvidin, petunidin, peonidin, pelargonidin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">black berries, black currant and blue berries</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-inflammatory effect, Inhibition of proliferation, activation of apoptosis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-ijms-20-04291" ref-type="bibr">30</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="ijms-20-04291-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">ijms-20-04291-t002_Table 2</object-id><label>Table 2</label><caption><p>Flavonoids tested lung cancer treatment, preclinical studies emphasis on the molecular mechanism of action.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Phycochemical Class</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Phytochemicals</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dose</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">In Vitro Models</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">End-Point</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Effects</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Molecular Target</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Flavones</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Lutein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20&#x02013;160 &#x003bc;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI-H460, HEK-293T cell line</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Apoptosis assay, western blotting, RT-PCR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Apoptosis activation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bad&#x02193;, Bcl-2&#x02193;, Bax&#x02193;, caspase-3&#x02193; and Sirt1&#x02193;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B63-ijms-20-04291" ref-type="bibr">63</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#x02013;100 &#x003bc;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H1299 and -H460 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunoblot analysis, PI assay</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Apoptosis activation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">p38/ROS/caspase cascade&#x02191;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B33-ijms-20-04291" ref-type="bibr">33</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Apigenin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#x02013;100 &#x003bc;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MTT, colony assay, Transwell assay, western blot</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">anti-proliferation, anti-migration, and anti-invasion effects</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02193;Akt<break/>affecting<break/>PI3K signaling</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B31-ijms-20-04291" ref-type="bibr">31</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5&#x02013;80 &#x003bc;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549, H1975, and HCC827 NSCLC cell lines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Transwell migration and invasion assays, RT-PCR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of the migration/invasion of NSCLC cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Akt and Snail/Slug &#x02191;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B32-ijms-20-04291" ref-type="bibr">32</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Baicalein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#x02013;100 &#x003bc;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549 and H1299 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Western blot, QRT-PCR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of cell proliferation, down-regulation of Notch1 and hes-1 expression</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cyclin D1 and CDK1&#x02193;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B72-ijms-20-04291" ref-type="bibr">72</xref>]</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Flavonols</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Quercertin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#x02013;200 &#x000b5;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">JB6 Cl41 cells and A549</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anchorage-independent transformation assay, Microscale thermophoresis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Suppression of cells proliferation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aurora B kinase&#x02193;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B23-ijms-20-04291" ref-type="bibr">23</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#x02013;200 &#x000b5;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI-H358 and A549 cells.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Apoptosis, microarray</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">antiproliferative effect</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Caspase-3&#x02191;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B50-ijms-20-04291" ref-type="bibr">50</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kaempferol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1&#x02013;50 &#x003bc;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549 cell line</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MTT test, Transfection, PCR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">inhibition of cell proliferation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STAT3&#x02193;, claudin-2&#x02193;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B24-ijms-20-04291" ref-type="bibr">24</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fisetin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#x02013;40 &#x003bc;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MTT test, RT-qPCR, flow-cytometry</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Apoptosis activation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ERK1/2&#x02193;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B46-ijms-20-04291" ref-type="bibr">46</xref>]</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Flavnones</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Hesperetin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#x02013;100 &#x003bc;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RT-PCR, western blot</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">inhibition of cell proliferation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ERK1/2&#x02193;, HFKb-p65&#x02193;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B69-ijms-20-04291" ref-type="bibr">69</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50&#x02013;125 &#x000b5;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">inhibition of cell proliferation and cell cycle progression</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B35-ijms-20-04291" ref-type="bibr">35</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Naringenin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#x02013;300 &#x000b5;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A 549 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RT-PCR, western blot</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">suppression of Akt activity and the downregulation of MMP-2 and -9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Akt&#x02193;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B48-ijms-20-04291" ref-type="bibr">48</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#x02013;500 &#x000b5;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A 549 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Apoptosis assay, western blot</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cells apoptosis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bid and DR5&#x02191;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B64-ijms-20-04291" ref-type="bibr">64</xref>]</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Flavanols</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">EGCG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#x02013;40 &#x000b5;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H1299 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell proliferation, apoptosis assay, western blot</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">suppressing proliferation, inducing apoptosis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PI3K/Akt&#x02193;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B65-ijms-20-04291" ref-type="bibr">65</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#x02013;40 &#x000b5;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell culture and transfection, Western blot, Flow cytometry</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Decreased EGF-induced EGFR, Akt and ERK1/2 activation.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EGFR&#x02193;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B45-ijms-20-04291" ref-type="bibr">45</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EGCG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#x02013;40 &#x000b5;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549 and NCI-H1299 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scattering assay, wound healing assay, in vitro invasion assay, qRT-PCR, Western blot, confocal microscopy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell proliferation, EMT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TGF&#x003b2;&#x02193;, Smad2&#x02193; and Erk1/2&#x02193;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B36-ijms-20-04291" ref-type="bibr">36</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EGCG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#x02013;100 &#x000b5;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HAT activity assays, Immunoprecipitation and western blot analysis, RT-PCR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TGF-&#x003b2;1-induced EMT inhibition</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TGF&#x003b2;1&#x02193;, Smad2&#x02193;, Smad3&#x02193;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B73-ijms-20-04291" ref-type="bibr">73</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Isoflavones</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Daidzein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#x02013;60 &#x000b5;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSCLC cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TUNEL assay. Real-time PCR and western blotting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inducing apoptosis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STK3&#x02193;, STK4&#x02193;, YAP1&#x02193;, caspase3&#x02193;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B49-ijms-20-04291" ref-type="bibr">49</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Genistein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#x02013;100 &#x000b5;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H446 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Apoptosis assay, colony assay, RT-PCR, western blot</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">apoptosis and G2/M phase cell cycle arrest</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cdc25B&#x02193;, cyclin B1&#x02193;, survivin&#x02193;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B37-ijms-20-04291" ref-type="bibr">37</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#x02013;100 &#x000b5;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Apoptosis assay, qRT-PCR, Western blot</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of cell proliferation, cells apoptosis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bax&#x02191;, Bcl-2&#x02193;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B66-ijms-20-04291" ref-type="bibr">66</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Anthocyanidins</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Delphinidin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#x02013;80 &#x000b5;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell viability assay, Western blot, RT-PCR, Matrigel plug assay</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">suppression of the ERK, mTOR, and p70S6K pathways</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIF-1&#x003b1;&#x02193; VEGF&#x02193;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B70-ijms-20-04291" ref-type="bibr">70</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5&#x02013;60 &#x000b5;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCI-H441, SK-MES-1 and A549</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Western blot, Cell viability assay</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Apoptosis and angiogenesis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02191;caspase-3/9, &#x02193; anti-apoptotic proteins (Bcl2, Bcl-xL and Mcl-1), &#x02191;pro-apoptotic proteins (Bax and Bak);&#x02193;EGFR and VEGFR2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B71-ijms-20-04291" ref-type="bibr">71</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="ijms-20-04291-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">ijms-20-04291-t003_Table 3</object-id><label>Table 3</label><caption><p>Flavonoids as miRNA modulators with implications in lung cancer therapy: Preclinical evidences.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Natural Compound</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Preclinical Model</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">miRNA Targeted</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gene Targeted</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target Mechanism</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Technology Approach</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">EGCG (0&#x02013;50 &#x000b5;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CL13 cells, H1299, H460 and A549</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">miR-210 (&#x02191;)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIF-1&#x003b1; (&#x02193;)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">reduction of cell growth, hypoxia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Microarray, RT-PCR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B84-ijms-20-04291" ref-type="bibr">84</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">miR-212 (&#x02193;)<break/>miR-155 (&#x02191;)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MAPK</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">inhibition of proliferation and migration</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NGS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B81-ijms-20-04291" ref-type="bibr">81</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quercetin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">miR-16 (&#x02191;)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Claudin-2 (&#x02193;)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Decrease of tight junction mechanisms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">qRT-PCR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B88-ijms-20-04291" ref-type="bibr">88</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Genistein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">miR-27a (&#x02193;)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MET (&#x02191;)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">apoptosis and promotes caspase-3/9 activation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Apoptosis assay, western blotting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B85-ijms-20-04291" ref-type="bibr">85</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kaempferol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">miR-340 (&#x02191;)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cyclin D1 (&#x02193;), PTEN (&#x02191;)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell apoptosis, inhibition of proliferation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Apoptosis assay, qRT-PCR, western blotting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B34-ijms-20-04291" ref-type="bibr">34</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="ijms-20-04291-t004" orientation="portrait" position="float"><object-id pub-id-type="pii">ijms-20-04291-t004_Table 4</object-id><label>Table 4</label><caption><p>The effects of combined lung cancer treatment with flavonoids: Molecular evidences in preclinical studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Phytochemicals</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Chemotherapeutic</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Biological System</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Biological Effect</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">EGCG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cisplatin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549, H460 and H1299 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">enhances cisplatin sensitivity, NEAT1 upregulates EGCG-induced CTR1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B93-ijms-20-04291" ref-type="bibr">93</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Metformin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549, H1299 and H460 human NSCLC cell lines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">suppressing the Nrf2/HO-1 signaling pathway</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B94-ijms-20-04291" ref-type="bibr">94</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cisplatin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H1299 and Lu99 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">downregulation of AXK and TYRO3 receptor tyrosine kinases</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B104-ijms-20-04291" ref-type="bibr">104</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quercetin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gemcitabine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549 and H460 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of cancer cell growth and sensitized cancer cells to gemcitabine by quercetin, apoptosis via inhibiting HSP70 expression.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B95-ijms-20-04291" ref-type="bibr">95</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fisetin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paclitaxel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Synergic effect of combination treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B99-ijms-20-04291" ref-type="bibr">99</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Genistein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Radiotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stimulation of apoptosis, reducing plasmic Bcl-xL levels</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B101-ijms-20-04291" ref-type="bibr">101</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Baicalein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cisplatin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549/ /CDDP cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Induction of apoptosis via PI3K/Akt/NF&#x003ba;B pathway</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B102-ijms-20-04291" ref-type="bibr">102</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diosmetin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paclitaxel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549, H1299, H460, SPC-A1, H441, H1650, Calu-3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cells apoptosis, increasing paclitaxel efficacy, ROS accumulation, PI3K/Akt/GSK-3&#x003b2;/Nrf2 pathway disruption</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B103-ijms-20-04291" ref-type="bibr">103</xref>]</td></tr></tbody></table></table-wrap></floats-group></article>